


August 2019, Vol 6, No 8

# MSD

Medical Science & Discovery



- **MDCT virtual bronchoscopy with fiber optic bronchoscopy comparison**
- **Open globe injuries**
- **Eosinophilic lung diseases**

**International Journal of Medical Science and Discovery**  
**Open Access Scientific Journal**  
**[www.medscidiscovery.com](http://www.medscidiscovery.com),**  
**Lycia Press London UK ISSN: 2148-6832**

Medical Science and Discovery (<http://www.medscidiscovery.com>) is an international open access, peer-reviewed scientific research journal that provides rapid publication of articles in all disciplines of human health, clinical and basic medical science such as Biophysics, Biochemistry, Histology, Physiology, Genetics, Pathology, Toxicology, Anatomical Sciences, Pharmacology, Embryology, Internal and Surgical Medicine.

The policy of top priority of MSD is to put forward and highlight medical innovations and inspiring patents.

MSD offers an exceptionally fast publication schedule including prompt peer-review by the experts in the field and immediate publication upon acceptance. The editorial board aims at reviewing the submitted articles as fast as possible and promptly including them in the forthcoming issues.

This journal is published under ethical publishing policy of international scientific Bioethics and publication rules.

MSD supports the Open Access Initiative. Abstracts and full texts (HTML and PDF format) of all articles published by MSD are freely accessible to everyone immediately upon publication.

**Indexed Databases:** Chemical Abstracts (CAS), Index Copernicus, Open Air, ULRICHS Database, Proquest, Advanced Science Index, Turkish Citation Index, Research Bible, Scholar Google, NLM Catalog

**Medical Science and Discovery is an international open access, peer-reviewed scientific research journal.**

**ISSN: 2148-6832 (Print) E-ISSN: 2148-6832 (Online)**

**Category: Multi Disciplinary Health Science Journal**

**Abbreviated key title: Med. Sci. Discov.**

**Frequency: Monthly**

**Review System: Double Blind Peer Review**

**Circulation: Globally, Online, Printed**

**Article Processing Charge (APC): Free**

**Licensing: CC-BY-NC 4.0 International License Environmental**

**Editor-in-Chief: Assoc. Prof. Dr. Dr. Ahmad Rajabzadeh, Anatomical Department of Lorestan, University of Medical Sciences, Tabriz, Iran**

**Established: 30.04.2014**

**Web address: [www.medscidiscovery.com](http://www.medscidiscovery.com); <http://dergipark.ulakbim.gov.tr/msd>**

**E-mail : [editor \[at\] medscidiscovery.com](mailto:editor[at]medscidiscovery.com)**

**Phone : +44 020 3289 9294**

**Design and preparation of PDFs, Language editing, Web site design, Graphical design Services of international Journal of Medical Science and Discovery has been contracted with Lycia Press LONDON, UK (as Publisher), by the MSD Board of Directors**

**Publisher: Lycia Press Inc.**

**Address: 3rd Floor 86 - 90 Paul Street, EC2A 4NE, London, UK**

**Web address: [www.lycians.com](http://www.lycians.com)**

**Phone : +44 020 3289 9294**

**E-mail : [office \[at\] lycians.com](mailto:office[at]lycians.com)**

**E-mail : [info \[at\] lycians.com](mailto:info[at]lycians.com)**

## Honorary Editors

We are very grateful to our honorary editors for their contribution to science

Prof. Dr. Aziz Sancar  
University of North Carolina, Dept. of Biochemistry-Biophysics, Chapel Hill, NC, USA  
E-mail: aziz\_sancar [at] med.unc.edu

Prof. Dr. Giancarlo BAROLAT  
Barolat Institute, 1721 E 19th Ave #434, Denver, CO 80218, USA  
E-mail: gbarolat [at] verizone.net

Prof. Dr. Joyce REARDON  
University of North Carolina, Dept. of Biochemistry-Biophysics, Chapel Hill, NC, USA  
E-mail: biocjtr [at] gmail.com

Prof. Dr. Metin TULGAR  
Yuzuncu Yil University, School of Medicine, Dept. of Biophysics, Van, Turkey  
E-mail: prof.tulgar [at] gmail.com

## Editor in Chief

Assoc. Prof. Dr. Asghar Rajabzadeh  
Anatomical Department, Lorestan University of Medical Sciences, Khorramabad, Iran  
E-mail: editor [at] medscidiscovery.com  
E-mail: dr.a\_rajabzadeh [at] yahoo.com  
Phone: +98 938 472 7705

## Deputy Editors

Assoc. Prof. Dr. Michael George KEMP  
Wright State University, Biological Sciences Bldg II 148, 3640 Colonel Glenn Hwy, Dayton, OH 45435-0001 USA  
E-mail: mike.kemp [at] wright.edu  
Fax: +1 (937) 775-2614

Assoc. Prof. Dr. Zafer AKAN  
Co-Founder MSD, Lycia Press., 3rd Floor 86 - 90 Paul Street, EC2A 4NE, London, UK  
E-mail: zafer\_akan [at] hotmail.com  
Phone: +44 0 203 289 9294

## Editorial Board Members

Prof. Dr. Arash KHAKI  
Islamic Azad university ,Tabriz branch ,Dept. of Pathology, Tabriz Iran  
E-mail: arashkhaki [at] yahoo.com

Ph.D. Nezahat Ozlem Arat  
5380 Avenue du Parc Apt 4, H2V4G7, Montreal, QC, Canada  
E-mail: aratzlem[at] gmail.com

Prof. Dr. Nobuo INOTSUME (Vice-president)  
Hokkaido Pharmaceutical University, Clinical Pharmacology, Hokkaido AC, JAPAN  
E-mail: nobuo\_inotsume [at] hokuyakudai.ac.jp

Ph.D. Ozdemirhan SERCIN  
Interdisciplinary Research Institute, Université Libre de Bruxelles, Belgium  
E-mail: ozdemirhan.sercin [at] gmail.com

Ph.D. Shobhan GADDAMEEDHI  
Washington State University College of Pharmacy, Dept. of Experimental and Systems Pharmacology, Spokane, WA, USA  
E-mail: shobhan.gaddameedhi [at] wsu.edu

Ph.D. Younes El Bouzekri EL IDRISI  
Place Aboubakr, Imm 22, App 6, Bd Fal ould oumeir, Agdal Rabat  
E-mail: y.elbouzekri [at] gmail.com

Ph.D. Christopher SCHMITT  
University of California, San Francisco Cardiovascular Res. Inst. CA, USA  
E-mail: schmittce [at] gmail.com

Ph.D. Yusuf Kemal Demir  
Research and Development Scientist, Prinst Pharmaceuticals, North Carolina, USA  
E-mail: phdykd [at] gmail.com

## Lycia Press Inc. Editorial Office

Language Editor Elena JALBA  
Reading University, London, UK  
E-mail: office [at] lycians.com

## Instruction for Authors


- **Important**
- MSD journal team, is committed to deterring plagiarism, including self-plagiarism. Your manuscripts will be screened for similarity detection with iThenticate, Similarity rate is expected under the %30 except for material and method section.
- For research studies using human or animal subjects, the trial's design, conduct and reporting of results must conform to Good Clinical Practice guidelines (such as the Good Clinical Practice in Food and Drug Administration (FDA)-Regulated Clinical Trials (USA) or the Medical Research Council Guidelines for Good Clinical Practice in Clinical Trials (UK)) and/or to the World Medical Association (WMA) Declaration of Helsinki
- Dear Authors, please upload just these three files to the manuscript submission system for article submissions.
- **1- Title Page Sample**
- **2- Manuscript Sample**
- **3- Copyright Transfer and Author Consent Form**
- Please select Keywords from the MESH source
- (<https://www.nlm.nih.gov/mesh/MBrowser.html>)
- Manuscripts should be prepared in accordance with the "Uniform Requirements for Manuscripts Submission to Biomedical Journals" proclaimed by the International Committee of Medical Journal Editors ([www.icmje.org](http://www.icmje.org)).
- MSD uses vancouver reference style, please prepare articles due to Vancouver reference style rules.
- Manuscript Preparation Rules
- 1.Cover letter
- a- A statement that the manuscript has been read and approved by all the authors.
- b- That the requirements for authorship have been met for all the authors, based on the criteria stated by ICMJE.
- c- Approval of all the authors regarding the order in which their names have appeared.
- d- That each author confirms the manuscript represents honest work.
- e- The name, address, and telephone number of the corresponding author who is responsible for communicating with other authors about revisions and final approval.
- f- The letter should give any additional information that may be helpful to the editor, such as the type or format of the article. If the manuscript has been submitted previously to another journal or in another language, it is helpful to include the previous editor's and reviewers' comments with the submitted manuscript, along with the authors' responses to those comments. Submitting previous evaluatory review of another journal accelerates the review process.
- g- For accepted manuscripts, the authors are requested to fill and sign the journal's cover letter to express their consent for its publication.
- h- To reproduce published material, to use illustrations or tables or report information about identifiable people, the author should submit a copy of the permission with the manuscript to the journal.
- 2.Top Ethic Committee Approval
- Inclusion of the approval letter from the relevant Ethics Committee or Institution's Review Board regarding the research protocol and the rights of the subjects (if applicable to the study)
- 3.Top Consent Form
- Attach a copy of the consent form to the letter, if applicable. Consent forms would be evaluated by the Ethics Committee and then signed by the participant.
- 4.Top RCT or NCT Registration
- Emailing the letter denoting registration of RCTs or NCTs in domestic or international databases (The trial's registration number needs to be mentioned, too).
- 5. Manuscripts submitted in English, must be type written, double-spaced, on good quality A4 paper, or paper of similar format. Authors are requested to reserve margins of at least 2.5cm all around the paper. Original drawings of photos, tables and figures should be furnished together with the manuscripts.
- 6. Manuscripts should be kept to a minimum length and should be subdivided into labeled sections (Title page, Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement, and References).
- 7. A title page is to be provided and should include the title of the article, authors' names with full first name (with degrees), authors' affiliation, suggested running title and corresponding author. The affiliation should comprise the department, institution (usually university or company), city and state (or nation). The suggested running title should be less than 50 characters (including spaces) and should comprise the article title or an abbreviated version thereof. For office purposes, the title page should include the name and complete mailing address, telephone and fax number, and email of the one author designated to review proofs.
- 8. An abstract no longer than 250 words for reviews and research articles is to be provided as the second page. Abstract should be structured as objective(s) (including purpose setting), materials and methods, results, and conclusion..

## Instruction for Authors

- 9. A list of 3-8 keywords, chosen from the Medical Subject Headings (MeSH) list <http://www.nlm.nih.gov/mesh/MBrowser.html>, is to be provided directly below the abstract. Keywords should express the precise content of the manuscript, as they are used for indexing purposes. Provide abbreviations and nomenclature list in an alphabetical order and non-standard abbreviations contained in the manuscript (excluding references) with definitions after the keywords. Use abbreviations sparingly and only when necessary to save space, and to avoid repeating long chemical names or therapeutic regimes. In a figure or table, define the abbreviations used in a footnote.
- 10. Tables in limited numbers should be self-explanatory, clearly arranged, and supplemental to the text. The captions should be placed above.
- 11. Figures should be utilized only if they augment understandability of the text. The captions should be placed below. Drawings and graphs should be professionally prepared in deep black and submitted as glossy, black and white clean Photostats. Professionally designed computer generated graphs with a minimum of 300 DPI laser printer output is preferable. Color photographs are welcomed.
- 12. The same data should not be presented in tables, figures and text, simultaneously.
- 13. MSD uses Vancouver referencing Style. References in limited numbers and up-to-dated must be numbered consecutively in order of citation in the text (number in parentheses). Periodical titles should be abbreviated according to the PubMed Journals Database (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=journals>). Print surnames and initials of all authors when there are six or less. In the case of seven or more authors, the names of the first six authors followed by et al. should be listed.
- Please check all references with EndNote referencing System. Please check out and Download Vancouver Endnote Style.
- **Type of Articles**
- Type of articles are based on PubMed definitions. For more info please refer to: <http://dtd.nlm.nih.gov/publishing/tag-library/3.0/n-w2d0.html>
- **Editorial :**
- Editorial is Opinion piece, policy statement, or general commentary, typically written by staff of the publication (The similar value "article-commentary" is reserved for a commentary on a specific article or articles, which is written by an author with a contrasting position, not an editor or other publication staff.)
- **Letters to the Editor about a recent journal article :**
- Letters referring to a recent article in this journal must be received within three months of its publication. For example, a letter referring to an article published in the January issue must be submitted online no later than March 31st. Letters submitted after the allowed time will not be considered.
- The text, not including references, must not exceed 700 words. A maximum of three authors and 10 references are allowed. Neither tables nor figures are allowed.
- Letters to the Editor NOT referring to a recent journal article :
- Original research that is of interest but does not fulfill all the requirements needed for publication as a full-length manuscript can be submitted as a letter to the editor. The letter must have a title and a maximum of three authors.
- The text, not including references, tables, figures or legends must not exceed 700 words. No more than 10 references and either one table or one figure are allowed.
- Word Count Limit: Letters should contain 500 - 700 words, maximum number of references is 10, maximum Number of illustrations/Tables is 1.
- **Original Article:**
- The content of the paper must justify its length. For reports of original investigative work, traditional division into sections is required: Title, Keywords, Addresses and which author address for correspondence, Structured abstract, Background, Objectives, Materials/Patients and Methods, Results, Discussion, References and Acknowledgements, Legends for display items (Figures and Tables).
- Original Research articles should contain 2500 - 3500 words, maximum number of references is 35, maximum Number of illustrations/Tables is 5.
- **Review Article :**
- Review Articles should contain 3500 - 4000 words, maximum number of references is 50, maximum number of illustrations/Tables is 5. In a review article both abstract and text of the manuscript, include following items:
- 1) Context: Include 1 or 2 sentences describing the clinical question or issue and its importance in clinical practice or public health.
- 2) Evidence Acquisition: Describe the data sources used, including the search strategies, years searched, and other sources of material, such as subsequent reference searches of retrieved articles. Explain the methods used for quality assessment and the inclusion of identified articles.
- 3) Results: Address the major findings of the review of the clinical issue or topic in an evidence-based, objective, and balanced fashion, emphasizing the highest-quality evidence available.
- 4) Conclusions: Clearly state the conclusions to answer the questions posed if applicable, basing the conclusions on available evidence, and emphasize how clinicians should apply current knowledge.

## Instruction for Authors

- **Case Report**
- A case report is a case study, case report, or other description of a case that should contain 1500 - 2000 words with a structured abstract of 200 words maximum. Case reports should comprise sections of Introduction, Case Presentation, and Conclusions in Abstract and Introduction, Case Presentation, and Discussion in full text with not more than 2 tables or figures and up to 20 references.
- **Brief Report**
- Brief Reports should contain 1000 - 2000 words with a structured abstract of 200 words maximum. Short reports should comprise sections of Background, Objectives, Materials & Methods, Results and Discussion with not more than 2 tables or figures and up to 20 references.
- **Short Communication**
- Short Communication, follow the instructions for original articles, except that the total word number of the main text (excluding references, tables and figure legends) is limited to 2000 with no more than 2 figures and/or tables and no more than 15 references. An abstract, not exceeding 150 words, should be presented at the beginning of the article.
- **News**
- News should contain 1000 - 2000 words with a structured abstract of 200 words maximum. News should comprise sections of Background, Objectives, Materials & Methods, Results and Discussion with not more than 2 tables or figures and up to 20 references.
- **Publication Policies**
- Manuscripts, or the essence of their content, must be previously unpublished and should not be under simultaneous consideration by another Journal. The authors should also declare if any similar work has been submitted to or published by another Journal. By virtue of the submitted manuscript, the corresponding author acknowledges that all the co-authors have seen and approved the final version of the manuscript. The corresponding author should provide all co-authors with information regarding the manuscript, and obtain their approval before submitting any revisions. Manuscripts are only accepted for publication on the understanding that the authors will permit editorial amendments, though proofs will always be submitted to the corresponding author before being sent finally to press. Prior to the initial submission of a new manuscript, please carefully consider that all authors' names are included as no change to authors' details will be permitted after the acceptance. The decision to accept a contribution rests with the Editorial Board of the MSD.
- Manuscripts will be considered for publication in the form of original articles, Case report, short communications, Letter to editor and review articles. The work should be original or a thorough by an authoritative person in a pertinent field.
- **Peer review process**
- All submissions will be reviewed anonymously by at least two independent referees. All manuscripts will be acknowledged upon presenting to the Journal office, provided that all stated requirements are met. Authors are encouraged to suggest names of three expert reviewers, but selection remains a prerogative of the Editor. The whole review process depends on receiving referees comments and revising the manuscripts based on these comments to the author. On receipt of the revised article from the author, and after final approving by referees, the letter of acceptance is issued to the author. Authors have the right to communicate to the editor if they do not wish their manuscript to be reviewed by a particular reviewer because of potential conflicts of interest. No article is rejected unless negative comments are received from at least two reviewers. **MSD employs double blind reviewing process, where both the referee and author remain anonymous throughout the process.**



## Instruction for Authors

- **Ethical Rules and Rights**

- **Conflicts of interest**

- Conflicts of interest arise when authors, reviewers, or editors have interests that are not fully apparent and that may influence their judgments on what is published. They have been described as those which, when revealed later, would make a reasonable reader feel misled or deceived. (The Committee on Publication Ethics (COPE) states in its Guidelines on Good Publication Practice 2003).

- Authors should disclose, at the time of submission, information on financial conflicts of interest or other interests that may influence the manuscript. Authors should declare sources of funding for the work undertaken.

- **Authors Responsibilities**

- 1. Authors must certify that their manuscript is their original work.
- 2. Authors must certify that the manuscript has not previously been published elsewhere, or even submitted and been in reviewed in another journal.
- 3. Authors must participate in the peer review process and follow the comments.
- 4. Authors are obliged to provide retractions or corrections of mistakes.
- 5. All Authors mentioned in the paper must have significantly contributed to the research. Level of their contribution also must be defined in the Authors Contributions section of the article.
- 6. Authors must state that all data in the paper are real and authentic.
- 7. Authors must notify the Editors of any conflicts of interest.
- 8. Authors must identify all sources used in the creation of their manuscript.
- 9. Authors must report any errors they discover in their published paper to the Editors.
- 10. Authors must not use irrelevant sources that may help other researches/journals.
- 11. Authors cannot withdraw their articles within the review process or after submission, or they must pay the penalty defined by the publisher.

- **Editorial Responsibilities**

- 1. Editors (Associate Editors or Editor in Chief) have complete responsibility and authority to reject/accept an article.
- 2. Editors are responsible for the contents and overall quality of the publication.
- 3. Editors should always consider the needs of the authors and the readers when attempting to improve the publication.
- 4. Editors should guarantee the quality of the papers and the integrity of the academic record.
- 5. Editors should publish errata pages or make corrections when needed.
- 6. Editors should have a clear picture of a researchs funding sources.
- 7. Editors should base their decisions solely one the papers importance, originality, clarity and relevance to publications scope.
- 8. Editors should not reverse their decisions nor overturn the ones of previous editors without serious reason.
- 9. Editors should preserve the anonymity of reviewers (in half blind peer review journals).
- 10. Editors should ensure that all research material they publish conforms to international accepted ethical guidelines.
- 11. Editors should only accept a paper when reasonably certain.
- 12. Editors should act if they suspect misconduct, whether a paper is published or unpublished, and make all reasonable attempts to persist in obtaining a resolution to the problem.
- 13. Editors should not reject papers based on suspicions; they should have proof of misconduct.
- 14. Editors should not allow any conflicts of interest between staff, authors, reviewers and board members.
- 15. Editors must not change their decision after submitting a decision (especially after reject or accept) unless they have a serious reason.

- **The Journal's Policy on Plagiarism**

- Any practice of plagiarism will not be tolerated by the journal regarding submitted manuscripts. Non-identifiable quoted segments of articles or close paraphrases from other author/s or even submitting the author's previously published work are known as the act of plagiarism by this journal unless proper use of quotations or paraphrasing with decent citation or referencing are in place. Heavy use of one or a couple of articles is discouraged, even if paraphrased fully. Advertent practice of plagiarism will abort reviewing process or later submission to this journal. All submitted articles will evaluate by iThenticate software belonged to cross check for stop any plagiarism and improve publication quality.

## Instruction for Authors

- **The Journal's Policy on Plagiarism**
- Any practice of plagiarism will not be tolerated by the journal regarding submitted manuscripts. Non-identifiable quoted segments of articles or close paraphrases from other author/s or even submitting the author's previously published work are known as the act of plagiarism by this journal unless proper use of quotations or paraphrasing with decent citation or referencing are in place. Heavy use of one or a couple of articles is discouraged, even if paraphrased fully. Advertent practice of plagiarism will abort reviewing process or later submission to this journal. All submitted articles will evaluate by iThenticate software belonged to cross check for stop any plagiarism and improve publication quality.
- **Statement of Human and Animal Rights**
- All submitted articles involving human experiments should be performed only in accordance with the ethical standards provided by the responsible committee of the institution and in accordance with the Declaration of Helsinki (as revised in Edinburgh 2000), available at <http://www.wma.net/en/30publications/10policies/b3/index.html>. Papers describing animal experiments can be accepted for publication only if the experiment conforms the National Institute of Health Guide (National Institute of Health Publications No. 80-23, Revised 1978) for the care and use of Laboratory Animals for experimental procedure. Authors must provide a full description of their anesthetics and surgical procedures. All manuscripts reporting the results of experimental investigations involving human subjects should include a statement confirming the informed consent was obtained from each subject or subject's guardian.
- **Humans:** When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.
- **Animals:** When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.
- All animal or human subjects should be used after approval of the experimental protocol by a local ethics committee.
- **Acknowledgements**
- **Contributors:** In acknowledgement section, name people for their contributions or their permission to reproduce their published material, to use their illustrations or provide information about them- try to fully name people who have helped from the conception of the idea to adoption of the hypothesis, to finalization of the study, etc., earnestly. Statement of financial support: Aside from the title page, state any financial or other relationships that might lead to a conflict of interest.
- **Copyright**
- After acceptance and publication; Medical Science and discovery allows to the author's to hold the copyright without any restriction. Please complete copyright form and send via email to editor. Download MSD Copyright Transfer and Author Consent Form
- **Creative Commons License**
- This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.(CC BY NC).
- **Copyright 2019:** The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. All Rights reserved by international journal of Medical Science and Discovery.
- **Disposal of material**
- Once published, all draft copies of the manuscript, correspondence and artwork will be held at least for 6 months before disposal. Authors and Readers may find original PDF file of article on backup servers such as LOCKSS (<https://www.lockss.org/>)
- **Digital Object Identifier DOI**
- Once a manuscript is accepted for publication it will be provided with a registered DOI number following the acceptance decision. Manuscripts accepted for publication by the MSD will be published as ahead of print articles prior to the printing date of their scheduled issue. Corresponding author will be provided with a PDF Proof by the publisher once the production process of an accepted manuscript is over.



## Instruction for Authors

- **Article Processing Charge** is free
- MSD Article Submission Fee: Free
- MSD Fast Evaluation Process Fee: Free
- MSD Article Evaluation Fee: Free
  
- Lycia Press Proofreading Service Fee: Design and preparation of PDFs, Language editing, Graphical design Services of international Journal of Medical Science and Discovery has been contracted with Lycia Press LONDON, UK (as Publisher <https://lycians.com>), by the MSD Board of Directors. Proof Reading Service Fee depends on your manuscript. Please get contact with lycia press language office for your manuscripts proofreading cost info [office@lycians.com](mailto:office@lycians.com)
  
- **MSD revenue sources and Sponsorships**
- All costs arising from the publications are covered by the Sponsor Companies. Sponsorship request evaluates by the MSD Journal Management Board, Lycia Press and the sponsor company logos will be included on the back page of printed magazine and in the sponsor section of journal website
  
- **References**
- Committee on Publication Ethics (COPE). (2011, March 7). Code of Conduct and Best-Practice Guidelines for Journal Editors. Retrieved from [http://publicationethics.org/files/Code\\_of\\_conduct\\_for\\_journal\\_editors\\_Mar11.pdf](http://publicationethics.org/files/Code_of_conduct_for_journal_editors_Mar11.pdf)
- World Association of Medical Editors (WAME). Principles of Transparency and Best Practice in Scholarly Publishing. <http://www.wame.org/about/principles-of-transparency-and-best-practice>

## Contents

### Research Article

**In the evaluation of tracheobronchial lesions, MDCT virtual bronchoscopy with fiber optic bronchoscopy comparison / Pages: 136-144**

Zeyni Unverdi, Resat Kervancioglu, Mehmet Sait Menzilcioglu

**The effect of injury type and location on the prognosis of the patients with open globe injuries / Pages: 145-149**

Cezmi Dogan, Burak Mergen, Seda Sert, Gulsah Tezcan, Busenur Gonen, Umit Yasar Guleser, Osman Sevki Arslan

### Case Report

**Evaluation and treatment of the eosinophilic lung diseases in 7 patients / Pages: 150-159**

Tugce Uzar, Gozde Duyu, Ahmet Dirican, Selda Gunaydin, Nazli Topbasi, Hulya Bayiz, Şevket Özkaya

## In the evaluation of tracheobronchial lesions, MDCT virtual bronchoscopy with fiber optic bronchoscopy comparison

Zeyni Unverdi<sup>1\*</sup>, Resat Kervancioglu<sup>2</sup>, Sena Unverdi<sup>1</sup>, Mehmet Sait Menzilcioglu<sup>2</sup>

### Abstract

**Objective:** The aim of this study is compare multislice CT VB and FOB to assess tracheobronchial lesions with multislice CT VB.

**Material and Methods:** In the period between September 2012 and August 2013 found indications for bronchoscopy and the total of 44 patients underwent FOB and FOB MDCT-SB were included in the study to be evaluated. All patients underwent VB and/or FOB. In both methods, tracheobronchial tree were divided into 18 separate segments. FOB virtual bronchoscopic findings as the gold standard method to assess the results were considered. Accordingly, positive and negative predictive values of MDCT for VB, sensitivity, selectivity and specificity values were calculated.

**Results:** Patient ages 1 and 79 (mean:  $53 \pm 16$ ) of the patients ranged from 7 (16%) female and 37 (84%) were men. In FOB 16 narrowing, 9 congestion, 4 external compression, 11 mucosal abnormalities were found and in the VB 12 narrowing, 16 obstruction, 8 external compression detected. None of the 11 mucosal findings in the FOB could not be determined in VB. Patients detect in FOB 25 cases were detected in VB; two patients with lesions on the FOB, although not detected in the VB (false negative). In 14 cases both FOB and endoluminal lesion was detected in the VB. FOB lesions not seen in the VB lesion in 5 cases (false positive). According to these values, sensitivity 92%, specificity 73%, positive predictive value (PPV) of 82%, negative predictive value (NPV) 87%, Accuracy: 84%, respectively.

**Conclusion:** Both mucosal biopsies should not be made to give details because of disadvantages such as virtual bronchoscopy fob is not an alternative for the moment. However tracheobronchial tumor research, interventional bronchoscopic procedures and biopsy guidance, foreign body aspiration of the initial assessment, tracheal injury is evaluation and treatment planning, obstructive lesions of the distal show, stenosis evaluation of endobronchial abnormalities characterization and postoperative follow-up issues of virtual bronchoscopy, constantly evolving detector technology and software when placed through the right indications for routine use will take time, we believe that the rightful place.

**Keywords:** Virtual bronchoscopy, Fiberoptic bronchoscopy, MSCT, Tracheobrochial pathologies

### Introduction

The term virtual endoscopy (VE) refers to the use of computer software for the construction of realistic mucosal surface and intraluminal images of hollow organs. The earliest studies in this field date back to 1994 when Vining et al. carried out a virtual colonoscopy [1], while in 1996, the same researchers published the results of their studies into virtual bronchoscopy (VB) [2] and virtual cystoscopy [3]. The term VB refers to the computer-aided construction and examination of endoscopic images of the tracheobronchial tree using volumetric data obtained from scans of the thoracic cavity with a thin-slice spiral or multi-slice computed tomography (MSCT), similar to that used in fiberoptic bronchoscopy (FOB).

Assessments made from multiplanar images and a three-dimensional perception facilitates control over anatomical structures. Images of higher quality have been acquired with the introduction of MSCT, which was first introduced in 2000 and became rapidly widespread due to the avoidance of the disadvantages associated with spiral CT such as motion artifacts and time loss. The present study evaluates the success, limitations, advantages and disadvantages of MSCT-VB in demonstrating tracheobronchial system pathologies, and makes a comparison of fiberoptic bronchoscopy and VB in terms of diagnostic accuracy and success in the evaluation of tracheobronchial lesions.

Received 29-06-2019 Accepted 16-08-2019 Available Online 17-08-2019 Published 30-08-2019

1 Defa Life Hospital, Clinic of Radiology, Gaziantep, TR

2 Gaziantep University School of Medicine, Department of Radiology, Gaziantep, TR

\* Corresponding Author: Zeyni Unverdi E-mail: [zeyniunverdi@gmail.com](mailto:zeyniunverdi@gmail.com) Phone: +90 (312) 220 00 02



## Material and Methods

After obtaining the approval of the relevant ethics committee (Gaziantep University Ethics Committee) and written informed consent from all subjects, a total of 44 cases who were scheduled to undergo bronchoscopy and FOB were evaluated using MSCT and VB between September 2012 and August 2013.

For VB, the tracheobronchial system was scanned using a 64-detector (VCT XTe Light Speed, General Electric, Milwaukee, USA) MSCT in the axial plane with a slice thickness of 0.625 mm. The detector was configured with a collimation of 64x0.625 mm, a table rotation speed of 0.65 sec, 120 Kv, 120 mAs, a FOV of 25–50 mm and 1 pitch. Less than 1 cc of a contrast agent per body weight of the patient was injected intravenously as a bolus to the patients using a pump. Volumetric scanning was completed within 10 sec on average in a single breath, although this differed from patient to patient.

All axial images, with a slice thickness of 0.625 mm, were evaluated in the workstation. The virtual bronchoscopic images acquired using thoracic VCAR software in the navigation mode were evaluated by simultaneously displaying the images with axial, coronal, sagittal and curve MPR images on two screens, split into four and five quadrants. In the virtual bronchoscopic evaluation, the intraluminal appearance of the two main bronchi and segmental and subsegmental branches of the bronchi were examined starting from the proximal to the trachea, as in aFOB.

While advancing in the tracheobronchial tree, the images in the two planes were used to evaluate the localization, luminal wall and extraluminal structures. When needed, the three-dimensional external bronchial simulations were used to evaluate any lesions that extended beyond the tracheobronchial wall.

All patients underwent FOB with an Olympus bronchoscope, model LTF, type 160. The interval between the FOB and VB in each patient was a maximum of three days. The biopsy specimens obtained during FOB were evaluated by experienced pathologists (image 1).

### Statistical Analysis

FOB examinations are considered the optimum approach for the evaluation of VB results. Accordingly, true positive, true negative, false positive, false negative, specificity, sensitivity and accuracy values were calculated for MSCT-VB, with IBM SPSS software v15.0 used for the statistical analysis.

## Results

Included in the study were 44 patients in which FOB and MSCT-VB were performed independently. The mean age of the patients was  $53 \pm 16$  years with a range of 1–79 years; seven patients (16%) were female and 37 patients (84%) were male.

A total of 43 patients underwent bronchoalveolar lavage and a fine needle aspiration biopsy or histopathological sampling using surgical or radiological methods. The histopathological examinations revealed benign lesions in 12 patients (non-specific), squamous cell carcinoma in nine patients, adenocarcinoma in seven patients, small cell lung cancer in four patients, bronchiolitis obliterans with organized pneumonia (BOOP) in one patient, NSCLC-NOS in one patient, inflammatory myofibroblastic tumor in one patient, hydatid cyst in one patient, malignant epithelial tumor in one patient, malignant mesothelioma in one patient, granulomatous lesion (sarcoidosis or tuberculosis) in one patient and tuberculosis in one patient. The histopathological results of the patients are presented in Table 1.


Considering the trachea, two main bronchi and 18 segments in the lungs, a total of 968 areas in 44 patients were evaluated with FOB and VB. The rate of endoluminal lesions detected by VB was 4.4% and the rate of endoluminal lesions detected by FOB was 4.1%.

In terms of endobronchial lesions, FOB identified 16 stenoses, nine obstructions, four external compressions and 11 mucosal findings, whereas VB identified 12 stenoses, 16 obstructions and eight external compressions. None of the 11 mucosal findings on FOB were detected on VB. The distribution of the endobronchial lesions detected by both FOB and VB is presented in Table 2.


The localizations of the endobronchial lesions detected on VB and FOB are presented in Table 3. No significant difference was detected in diagnostic accuracy for the central and segmental branches in the virtual bronchoscopic evaluation ( $P < 0.05$ ).

In the comparison of FOB and VB, considering FOB as the optimum approach, 23 cases in which a lesion was detected on FOB were also detected on VB, whereas VB was unable to detect two cases in which FOB identified a lesion (false negative). FOB and VB identified no endoluminal lesions in 14 cases. VB revealed a lesion in five cases in which FOB did not identify any lesions (false positive). The comparison of diagnostic accuracy is shown in Figure 1 and Table 4; accordingly, sensitivity was 92%, specificity was 73%, positive predictive value (PPV) was 82%, negative predictive value (NPV) was 87% and accuracy was 84%.

**Image 1 :** A mass lesion that completely obstructs the left lower lobe bronchus by externally compressing it. FOB (A,B), 3D (C) , coronal (D) and VB (E,F) images.




A




B



C



D



E



F

**Table 1:** Distribution of histopathological results of the cases.

| Histopathology                           | Case Number |
|--|-------------|
| Benign (non-specific)                    | 12          |
| Squamous cell carcinoma                  | 9           |
| Adenocarcinoma                           | 7           |
| SCLC                                     | 4           |
| Chronic inflammation                     | 4           |
| NSCLC -NOS                               | 1           |
| Malignant epithelial tumor               | 1           |
| Malignant mesothelioma                   | 1           |
| Granulomatous lesion (sarcoidosis /tbc?) | 1           |
| Tuberculosis                             | 1           |
| Hydatid cyst                             | 1           |
| BOOP                                     | 1           |
| Inflammatory myofibroblastic tumor       | 1           |
| No biopsy                                | 1           |

**Table 2:** Distribution of endobronchial lesions detected on FOB and VB.

|     | Stenosis | Occlusion | External Compression | Mucosal Finding |
|-----|----------|-----------|----------------------|-----------------|
| FOB | 16       | 9         | 4                    | 11              |
| VB  | 12       | 16        | 8                    | 0               |

**Table 3:** Distribution of the localization of endobronchial lesions detected on FOB and VB.

| Lesion distribution according to FOB |                    |               |                |                    |           |    |
|--------------------------------------|--------------------|---------------|----------------|--------------------|-----------|----|
| Lesion distribution according to VB  | Trachea            | Main Bronchus | Lobar bronchus | Segmental Bronchus | No Lesion |    |
|                                      | Trachea            | 3             |                |                    |           |    |
|                                      | Main Bronchus      |               | 4              | 1                  |           |    |
|                                      | Lobar bronchus     |               |                | 5                  |           | 3  |
|                                      | Segmental Bronchus |               |                | 1                  | 12        | 2  |
|                                      | No Lesion          |               | 1              | 1                  |           | 14 |

**Table 4.** Evaluation of the diagnostic accuracy of the findings detected on VB.

|         | VB (+)  | VB (-)  | Total |
|---------|---------|---------|-------|
| FOB (+) | 23 (TP) | 2 (YN)  | 25    |
| FOB (-) | 5 (FP)  | 14 (TN) | 19    |
| Total   | 28      | 16      | 44    |

TP: True Positive, FN: False Negative, FP: False Positive, FN: False Negative

## Discussion

prompted the researcher to investigate alternative diagnostic methods. FOB is a similarly invasive diagnostic method, and although rare, complications may occur during the procedure. Bronchoscopy using alternative and noninvasive methods has become a popular topic in recent years, and has raised the interest of the imaging industry, resulting in a shift toward the pursuit of methods that take advantage of the advances in the computer, medical engineering and software fields. The emergence and development of the idea of VB, which dates back to the mid-1990s, was a result of technical advances and the pursuit of alternative methods [2, 3, 4]. At that time it became possible to transfer and process volumetric data on conventional axial images of tissue obtained to date through spiral or multi-slice CT systems on a separate computer. This allowed multiplanar reformatted images and virtual endoscopic images to be acquired. The direct visualization of the airways through FOB and the opportunity to obtain a biopsy instantly from the desired localization, however, have preserved the importance of this procedure, with has thus retained its value as the optimum approach. The availability of other diagnostic and therapeutic procedures, such as concurrent bronchial lavage, and obtaining culture material and removing existing foreign bodies can be regarded as other advantages of this method. There has been no change, however, in the invasiveness of the procedure, the need for sedation or the intolerance of some patients, even when performed with more flexible fiber optic catheters than a rigid bronchoscope [5, 6].

Although VB is performed using computer software, the experience of the operator is an important concern, as the region or localization of the lesion cannot be evaluated if orientation to the area is poor. VB should have a place in such evaluations, considering that it can be performed on existing CT images of the lungs, and the fact that it does not require a separate examination or patient preparation. Aside from clinical indications, VB can also be used for training and research purposes, with VB images similar to those of FOB being attained that can be used to teach and learn anatomical details of the tracheobronchial tree. VB allows chest disease specialists to practice, and permits an easier and more effective performance of a more invasive FOB if interpreted earlier [2, 7, 8].

Patients undergo 15–20 minutes of preparation for anesthesia before a conventional bronchoscopy, although the evaluation of more complicated cases may even require general anesthesia.

In terms of complications, VB is more advantageous than FOB. Unnecessary FOB examinations must be avoided, particularly in pediatric cases in whom complication rates can be as high as 7%. Haliloğlu et al. reported that unnecessary FOBs can be avoided through the use of VB [9]. Various retrospective studies have reported mortality rates of 0.008–0.04%, major complication rates of 0.05–3.4% and minor complication rates of a little below 10% [10, 11]. A prospective study, on the other hand, reported a mortality rate of 0.44%, a major complication rate of 1.65%

(such as severe hemorrhage, respiratory arrest, pneumonia, pneumothorax and severe airway obstruction) and a minor complication rate of 6.5% [12]. No complication was reported among the cases that underwent FOB in the present study.

Virtual bronchoscopic images can also be obtained using helical CT scans, although such images have a low spatial resolution and a prolonged acquisition time, and the very slow reconstruction also makes their use inconvenient. The introduction of multi-slice CT into practice has reduced the entire examination time to 15–20 seconds and the slice thickness to 0.5–1 mm, and so the resolution of three-dimensional imaging has increased. According to Lacasse et al. [13], an examination with a collimation of 3 mm and a slice interval of 1.5 mm lacks sufficient accuracy for the investigation of endoluminal lesions. The use of MSCT images has also increased diagnostic accuracy, while the use of faster computers with higher processing capacities has allowed the acquisition of virtual bronchoscopic and other reconstructed images in a short period of time [14]. A virtual bronchoscopy is more advantageous than FOB in terms of the total examination time, although a reduced procedural time can be regarded as a trivial advantage considering the time saved for the patient and physician and the lack of any increase in diagnostic accuracy. The reconstruction of images and virtual examinations after image acquisition depends on the radiologist, and the time spent on these procedures can vary considerably. The printing and saving of images and video images acquired through multidisciplinary works in hospitals lacking PACS, making them available to the clinician and then archiving them all require additional time. The time spent for VB is, on average, 15 minutes according to Wever et al. [15]. The time required for the reconstruction and examination of VB images ranged between 15 and 20 minutes in the present study, although this varied from one patient to another. The procedural time has decreased over time; although it does not seem likely that it will be further reduced in the near future. There have been studies attempting to reduce examination times through the provision of panoramic images or the use of developed automatic lesion detection software. It can currently be argued that VB is among the routine practices considering the time spent by a radiologist on VB.

One of the most significant differences between FOB and VB is that FOB is a dynamic procedure, which comes with its own advantages and disadvantages. Factors such as inspiration and expiration during FOB, cough reflex and continuous secretions that can be challenging for the clinician during the procedure are of no concern during VB. The procedure can be repeated any number of times in a VB, and there are no secretions that impair visibility. The images can be tracked from proximal to distal, and also from distal to proximal, allowing the visualization of endoluminal lesions from multiple perspectives. VB, however, lacks many of the important diagnostic advantages that come with FOB. The first of these is the inability with VB to observe the response of airways to respiratory movements and cough reflexes. A clinician can clearly observe the enlargement and narrowing of airways

during FOB, as well as segmental bronchial openings that open and close and the movements of cartilage and mucosal tissues. Irregular changes in the diameter of the trachea of different types that are diagnostic for tracheomalacia, diverticula and herniation's, and that become visible during inspiration, and movements of pedunculated lesions and their extensions can also be recognized during FOB. There is no opportunity to observe such movements in VB. In a study of 45 cases with a mean age of 4.4 years, Heyer et al. [16] reported an NPV of 54.5%, and attributed this low rate to five patients with tracheomalacia/bronchomalacia in the patient group. They reported in the study that CT images acquired during inspiration would not be diagnostic for tracheomalacia, but that a diagnosis could be established through a biphasic investigation on VB during inspiration and expiration. Secretions and mucous plugs may be misdiagnosed as mass lesions, and such conditions are the most common cause of false positive results in VB [9]. Secretions and coagulum were mistaken for stenosis in five patients in VB, being later identified as secretion and coagulum. The appearance of air-foam in the left bronchus was thought to be associated with secretions. Mucous plugs can be aspirated and the lumen or orifices can be opened during FOB. Furthermore, foreign bodies can be removed upon detection, while in virtual bronchoscopy, it is not possible to recognize such bodies or remove them through aspiration.

Virtual bronchoscopic images must be correlated with conventional images and multiplanar reformatted images to reduce false positive results and to avoid mistakes. In a study of 18 patients, Bernhardt et al. [6] found no significant difference between axial, MPR and VB images in the detection, localization and identification of the severity of stenosis, and recommended the combined use of images. Finkelstein et al. [17] reported a sensitivity of 82% and a specificity of 100% for VB, but identified no significant difference in terms of diagnostic accuracy when compared to high-resolution thoracic computed tomography scans in cancer patients. That said, the results from both methods were superior to axial images. Konen et al. [18] suggested that VB makes no contribution to cross-sectional images. Summers et al. [30] suggested that orientation would be better if VB is performed together with axial, coronal and sagittal imaging. Minghui et al. [19] found that the examination of MPR and VB images yielded higher sensitivity than that of FOB, and the same researchers suggested that this combination would be advantageous in terms of demonstrating the outer extensions of endoluminal lesions. Ferretti et al. [20] also stated that combined evaluations would increase diagnostic efficacy. Based on all the above findings, it would seem that conventional images must be combined with MPR and VB images, given that they cover each other's deficiencies and direct the radiologist to the correct diagnosis in patients with a suspected airway pathology. In our study, two screens were used while evaluating the VB images, with the correlation with MPR images investigated on the second screen. As mentioned in literature, the authors of the present study suggest that an evaluation of VB images in combination with axial and MPR images would increase diagnostic accuracy in the detection and grading of lesions.

The sensitivity of the method used for the detection of intraluminal lesions is related to the size of the lesion in VB, which can easily detect 5mm or larger endobronchial lesions. One study reported a sensitivity of 47–88% and a specificity of 48–89% in a patient group with lesions measuring 3–10 mm, while sensitivity and specificity rates increased by 20% and 34% respectively in lesions measuring 5–10 mm [21]. A 2-mm red nodule at the level of the vocal cord detected on FOB in patient number 9 could not be identified in VB, despite a repeat examination.

VB has increasing use in the grading of benign and malignant airway lesions, with high accuracy rates reported in the measurement of the depth and length of obstructive tracheobronchial lesions. Burke et al. [22] reported an excellent level of correlation between VB and FOB in the evaluation of the contours and shape of the stenotic segment. The present study found only a 10% difference in the rates of stenosis and lumen on VB and FOB. In 2002, Hoppe et al. [5] evaluated 200 bronchial segments using a 4-slice-MSCT with 2-mm collimation in a series of 20 patients. Their study reported high accuracy for MSCT in the evaluation of tracheobronchial lesions (accuracy in VB: 98%, accuracy in axial images: 96%; accuracy in coronal MPR images: 96%; accuracy in sagittal MPR images: 96.5%). The same study also reported that VB images have same diagnostic value as FOB in the evaluation of stenosis ( $r=0.91$ ), as well as the superiority of VB over other CT imaging methods in a semi-quantitative evaluation of stenotic segments. In another study by Hoppe et al. [23] comparing FOB and VB using a 4-slice MSCT and 1-mm collimation, VB was reported to have an accuracy of 95.5% in the evaluation of both central and segmental airway stenoses. Their study also reported that VB led to a higher number of false positive results in the segmental bronchi than in the central bronchia; and that VB has a positive predictive value of 40.9% in segmental branches and a positive predictive value of 84.4% in the central airways. Lacasse et al. [13] stated that a 3-mm collimation and a 1.5-mm slice interval could overlook 32% of lobar and segmental lesions, but that further studies of MSCT could increase the sensitivity and specificity. The present study compared central and segmental airway stenoses using statistical methods, and found no significant difference in the diagnostic accuracy of VB ( $P<0.05$ ). This can be attributed to the use of a 64-slice device with a lower collimation and higher resolution, as this allows the completion of the procedure using a single-breath-hold technique that minimizes respiratory artifacts. Finkelstein et al. [24] reported a sensitivity of 90% for VB in endobronchial lesions, a rate of 100% in obstructive lesions and a rate of 16% in mucosal lesions. In a collective analysis, sensitivity and specificity were reported to be 83% and 100%, respectively. In a study evaluating stenoses in tracheobronchial carcinomas, Rapp-Bernhardt et al. [6] reported a sensitivity of 94% and a specificity of 99.7% for VB. Liewald et al. [25] reported similar characteristics for VB and FOB in their evaluation of obstructive lesions. Table 8 summarizes the success rates in the identification of endoluminal lesions reported by various studies comparing VB and FOB in literature. Consistent with previous studies, the present study reports a sensitivity of



92%, a specificity of 73%, a positive predictive value (PPV) of 82%, a negative predictive value (NPV) of 87%, and an accuracy of 84%.

Some studies in literature have suggested that VB is as effective as FOB in identifying stenosis associated with a mass lesion, but that VB is not able to identify small infiltrations and to differentiate between complete and partial obstructions [26, 27]. The present study also found that VB can show severe stenosis as an occlusion. FOB identified 16 stenoses, nine obstructions and four external compressions, whereas VB identified 12 stenoses, 16 obstructions and eight external compressions. We believe that a simultaneous evaluation of VB images with MPR and axial images may reduce such failures. VB provides accurate information about the lumen diameter and the length of the stenotic segment, and such information is required for endobronchial procedures such as accurate stent placement, laser photocoagulation, brachytherapy and endobronchial cryotherapy [28, 17, 22, 29]. VB and three-dimensional images allow for the identification of the general appearance of the tracheobronchial tree and the delineation of the relationship between the lesion/stenosis and the surrounding pathological and normal tissues. VB can be beneficial in postoperative follow-up for the evaluation of the percentage of the remaining stenosis in the bronchial tree, the position of the stenosis and stent permeability [28, 26, 30]. It is also a useful noninvasive method for the evaluation of the suture line following organ transplantation, lobectomy and pneumectomy. McAdams et al. [28] showed that VB provides better results than axial CT images in the evaluation of the recipient's bronchial anastomosis following lung transplantation.

Obstructive lesions are one condition in which VB is superior to FOB. The clinician cannot pass beyond an obstructive lesion during FOB, and so the status of the more distal parts of the airway will remain uncertain. VB is not subject to such limitations and can easily pass beyond an obstructive lesion [28, 22, 25, 26]. The obstruction of distal parts of the tracheobronchial tree by secretion and blood prevents evaluation of these parts by VB, although this can be overcome through an examination of three-dimensional images together with axial images [26]. Bernhardt et al. [31] used VB to evaluate the parts distal to an obstructive lesion in five patients, and found no additional lesions. In our study, the distal parts of mass lesions that completely obstruct the lumen could not be evaluated in the "VB navigation mode", as the distal parts in all cases were filled with fluid (case numbers 6, 9, 17, 24 and 41). This problem was overcome, however, through the simultaneous examination of three-dimensional images together with axial and MPR images. No significant tracheobronchial lesion that would alter the statistical analysis was detected in any of these cases, although the need to delineate the airways that cannot be examined on FOB due to the presence of obstructive lesions seems to be one of the indications rendering VB inevitable. A clinician may proceed with a pathological diagnosis by carrying out a cellular sampling through bronchial lavage or biopsy, while VB offers no such opportunity. In addition, endoluminal surfaces are coded by a homogeneous single

color tone in VB, making the identification of mucosal color changes, superficial lesions and infiltrative extensions, vascularity, fragility and other details all of which can be observed during FOB, impossible. Lesions such as blood clots, mucus, tumors and foreign bodies, being coded by the same color tone, also reduce the selectivity of VB [9, 6, 19, 26]. It is a striking finding that VB showed normal results in 11 cases who were found to have a mucosal lesion on FOB. It can therefore be clearly expressed that VB is unable to identify mucosal changes and lesions. Furthermore, mucus, secretion and purulent fluid in five cases analyzed with VB led to false positive diagnoses of "lesion". Studies in literature mention "inability to detect mucosal lesions" and "inability to perform biopsy" as the most significant disadvantages of VB [17, 32, 33]. The authors of the present manuscript believe that VB should not be considered as an alternative to FOB, due to the inability to obtain a biopsy and to observe mucosal details.

Blind mediastinal lymph node biopsies with FOB have low sensitivity, particularly if the lesion has caused no change in the bronchial tree. The success rate is 72% for lesions that are observed during examination and only 36% if the lesion cannot be observed [34]. Whether or not a biopsy is performed will depend on estimations if a lesion cannot be detected and bronchial mucosa is normal, and this is the cause of rare false positive biopsies and a vast number of false negative biopsies [35]. A high rate of false negative biopsy results causes a delay in the staging and initiation of appropriate therapy, and thus leads to further interventional procedures [36]. Performing the procedure under the guidance of axial, coronal and sagittal reformatted images combined with VB images would be useful in determining the localization of the most appropriate biopsy site for lesions that are not causing bronchial distortion or mucosal changes [29, 36]. VB also aids the FOB operator in accessing the lesion and finding the most appropriate passageway, and can increase the effectiveness of a transbronchial biopsy in peripheral pulmonary lesions. McAdams et al. [28] reported a sensitivity rate of as high as 88% for transbronchial fine needle aspiration biopsies of the mediastinal and hilar lymph nodes under the guidance of VB in the detection of malignancy. Shinagawa et al. [37] reported the effectiveness of transbronchial biopsy using an ultra-thin bronchoscope guided by VB navigation in the diagnosis of peripheral pulmonary lesions smaller than 20 mm. Furthermore, biopsies of mediastinal lymph nodes smaller than 1.5 cm under the guidance of VB can be useful in increasing the accuracy of the results [36].

Conventional CT findings are also evaluated during VB, during which parenchymal findings, pleural thickening and effusions, pathologies of the thoracic wall and bones, pathologies of the abdominal structures that fall into the view of the examination, neck and thyroid pathologies, mediastinal pathologies and associated compressions-invasions, and vascular pathologies along with endobronchial lesions can be easily recognized. At the same time, when the mass lesions observed on VB are correlated with MPR images, the relationship with the surrounding tissues, the invasion findings and eligibility for

surgical resection can be evaluated. Bernhardt et al. [6] proposed VB as a useful method in the evaluation of mass invasion and staging when VB images are evaluated with axial and MPR images. Hoppe et al. [23] stated that axial and MPR images evaluated together with VB images yield similar sensitivity and specificity to VB, referring to it is a useful approach to the evaluation of mediastinal lymph nodes, and demonstrating their relationship with the surrounding tissue. In the present study, a mass lesion identified on VB was found to have invaded and narrowed the right pulmonary artery in one patient; A mass lesion in the upper lobe of the right lung in another patient extended into the spinal canal after eroding and destroying the upper thoracic vertebra and the neighboring ribs; and a mass lesion in another patient invaded the pericardium and mediastinal mass; while also invading most of the mediastinal vascular structures. The use of MSCT in examinations offers significant advantages. For example, it is highly possible to convert reconstruction algorithms into HRCT algorithms as thin slices are scanned with the spiral method. This allows soft tissue and bone tissue findings, while avoiding both interstitial findings and partial volume artifacts. Another advantage of a thin-slice examination is that it allows the three-dimensional reconstruction of the pulmonary nodules, thereby providing more detailed information about the nodule and allowing the more reliable follow-up of the nodule. Additional findings beyond the tracheobronchial tree were detected in most of the patients in the present study (Table 3).

VB is a useful and noninvasive means of evaluating foreign body aspirations and congenital airway anomalies in both pediatric and adult patients [15]. In their study, Konen et al. [18] reported that VB could be useful in the evaluation of the tracheobronchial tree for airway stenosis and compressive pathologies in pediatric patients. Tracheal stenosis was detected, the intermediary bronchi could not be observed, and the right upper, middle and lower lobes branched from the main bronchus in one patient in the present study, while another patient was found to have a medial accessory segmental bronchus in the left inferior lobe.

When compared to FOB, VB offers the advantages of being non-invasive, requires no anesthesia or sedation, can be repeated a number of times, permits imaging from different angles, allows investigations for tracheobronchial tumors, permits access beyond obstructive lesions that cannot be observed on FOB, has a high sensitivity rate, offers the ability to show additional lesions and findings in the bronchial tree together with axial and MPR images, thereby aiding in the evaluation of lesions for operability, and allows the characterization of anomalies in the tracheobronchial structure.

As of this time, however, VB does not seem to be an alternative to FOB due to such associated disadvantages such as the inability to perform a biopsy, the low sensitivity in detecting lesions smaller than 5 mm, the inability to detect mucosal infiltration, the relatively low specificity rate when compared to high sensitivity rates, and the inability to offer real-time evaluation.

## Conclusion

The authors of the present manuscript believe that VB will find the place it deserves in routine use in time with the continued development of detector technologies and software, given its ability to guide interventional bronchoscopic procedures and biopsies, to aid in the initial evaluation and planning of treatment in foreign body aspirations, and to provide the clinician with the opportunity of practicing before following up tracheobronchial lesions with FOB.

**Acknowledgements:** None

**Conflict of Interest:** The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Author's Contributions:** ZU, RK, SU, MSM; Research concept and design, Patient examinations, Research the literature, preparation of the article MSM; Revision of the article.

## References

1. Vining D.j., Gelfand D.W., and Bechtold R.E., Technical feasibility of colon imaging with helical CT and virtual reality. *AJR Am J Roentgenol*, 1994; 162 (1): 104.
2. Vining D. J., Liu K., Choplin R. H., Haponik E. F. Virtual bronchoscopy: relationships of virtual reality endobronchial simulations to actual bronchoscopic findings. *Chest*, 1996; 109(2): 549-553
3. Vining D. J., Zagoria R. J., Liu K., Stelts D. CT cystoscopy: an innovation in bladder imaging. *AJR. American journal of roentgenology*, 1996; 166(2): 409-410.
4. Vining D. J. Virtual endoscopy: is it reality?. *Radiology*, 1996; 200(1):30-31.
5. Hoppe H., Walder B., Sonnenschein M., Vock P., Dinkel H. P. Multidetector CT virtual bronchoscopy to grade tracheobronchial stenosis. *American Journal of Roentgenology*, 2002; 178(5), 1195-1200.
6. Rapp-Bernhardt U., Weite T., Doehring W., Kropf S., Bernhardt T. M. Diagnostic potential of virtual bronchoscopy: advantages in comparison with axial CT slices, MPR and mIP?. *European radiology*, 2000; 10(6), 981-988.
7. Crawford S. W., Colt H. G. Virtual reality and written assessments are of potential value to determine knowledge and skill in flexible bronchoscopy. *Respiration*, 2004; 71(3): 269-275.
8. Buthiau D., Antoine E., Piette J. C., Nizri D., Baldeyrou P., Khayat, D. Virtual tracheo-bronchial endoscopy: educational and diagnostic value. *Surgical and Radiologic Anatomy*, 1996; 18(2): 125-131.
9. Haliloglu M., Ciftci A. O., Oto A., Gumus B., Tanyel F. C., Senocak M. E., et al. CT virtual bronchoscopy in the evaluation of children with suspected foreign body aspiration. *European journal of radiology*. *Eur J Radiol*, 2003; 48(2): 188-92.
10. Simpson F. G., Arnold A. G., Purvis A., Belfield P. W., Muers M. F., Cooke N. J. Postal survey of bronchoscopic practice by physicians in the United Kingdom. *Thorax*, 1986; 41(4), 311-317.
11. Berger I., Waldhorn R. E., Magruder S. Bronchoscopy in North America: The ACCP Survey. *Chest*, 1992; 102(5): 1638-1639.

12. Kaparianos A., Argyropoulou E., Sampsonas F., Zania A., Efremidis G., Tsiamita M. et al. Indications, results and complications of flexible fiberoptic bronchoscopy: a 5-year experience in a referral population in Greece. *Eur Rev Med Pharmacol Sci*; 2008; 12(6): 355-63.
13. Lacasse Y., Martel S., Hébert A., Carrier G., Raby, B. Accuracy of virtual bronchoscopy to detect endobronchial lesions. *The Annals of thoracic surgery*; 2004; 77(5): 1774-1780.
14. Sakarya M.E., Uzun K., Yuca K., Harman M., İşlek A., Temizöz O., Sezgi C., Trakeobronsiyalobstruksiyonlardamultidedektor BT sanalbronkoscopi. *TıpArastirmaDergisi*, 2004; 2(3):19-24.
15. De Wever W., Bogaert J., Verschakelen, J. A. Virtual bronchoscopy: accuracy and usefulness—an overview. In *Seminars in Ultrasound, CT and MRI*. WB Saunders., 2005; 26(5): 364-73.
16. Heyer C. M., Nuesslein T. G., Jung D., Peters S. A., Lemburg, S. P., Rieger, C. H., et al. Tracheobronchial anomalies and stenoses: detection with low-dose multidetector CT with virtual tracheobronchoscopy—comparison with flexible tracheobronchoscopy. *Radiology*, 2007; 242(2): 542-549.
17. Finkelstein S. E., Summers R. M., Nguyen D. M., Schrupp, D. S. Virtual bronchoscopy for evaluation of airway disease. *Thoracic surgery clinics*, 2004; 14(1): 79-86.
18. Konen E., Katz M., Rozenman J., Ben-Shlush A., Itzhak Y., Zeinberg, A. Virtual bronchoscopy in children: early clinical experience. *AJR. American journal of roentgenology*, 1998; 171(6): 1699-1702.
19. Xiong M., Zhang W., Wang D., Xu, J. CT virtual bronchoscopy: imaging method and clinical application. *Chinese medical journal*, 2000; 113(11): 1022-1025.
20. Ferretti GR., Thony F., Bosson JL., Pison C., Arbib F., Coulomb M. Benign abnormalities and carcinoid tumors of the central airways: diagnostic impact of CT bronchography. *American Journal of Roentgenology*, 2000; 174(5): 1307-1313.
21. Summers R. M., Selbie W. S., Malley J. D., Pusanik L. M., Dwyer A., Courcousakis, N. Holland, S. M. Polypoid lesions of airways: Early experience with computer-assisted detection by using virtual bronchoscopy and surface curvature. *Radiology*, 1998; 208(2): 331-337.
22. Burke A. J., Vining D. J., McQuirt Jr W. F., Postma G., Browne, J. D. Evaluation of airway obstruction using virtual endoscopy. *The Laryngoscope*, 2000; 110(1): 23-29.
23. Hoppe H., Dinkel H. P., Walder B., Von Allmen G., Gugger M., Vock, P. Grading airway stenosis down to the segmental level using virtual bronchoscopy. *Chest*, 2004; 125(2): 704-711.
24. Finkelstein S. E., Summers R. M., Nguyen D. M., Stewart IV J. H., Tretler J. A., Schrupp, D. S. Virtual bronchoscopy for evaluation of malignant tumors of the thorax. *The Journal of thoracic and cardiovascular surgery*, 2002; 123(5): 967-972.
25. Liewald F., Lang G., Fleiter T. H., Sokiranski R., Halter G., Orend, K. H. Comparison of virtual and fiberoptic bronchoscopy. *The Thoracic and cardiovascular surgeon*, 1998; 46(06): 361-364.
26. Fleiter T., Merkle E. M., Aschoff A. J., Lang G., Stein M., Görlich J., Sokiranski, R. Comparison of real-time virtual and fiberoptic bronchoscopy in patients with bronchial carcinoma: opportunities and limitations. *AJR. American journal of roentgenology*, 1997; 169(6): 1591-1595.
27. Adali F., Uysal A., Bayramoglu S., Guner N. T., Yilmaz G., Cimilli, T. Virtual and fiber-optic bronchoscopy in patients with indication for tracheobronchial evaluation. *Annals of thoracic medicine*, 2010; 5(2): 104.
28. McAdams H. P., Palme S. M., Erasmus J. J., Patz E. F., Connolly J. E., Goodman P., et al. Bronchial anastomotic complications in lung transplant recipients: virtual bronchoscopy for noninvasive assessment. *Radiology*, 1998; 209(3): 689-695.
29. Bricault I., Ferretti G., Cinquin, P. Registration of real and CT-derived virtual bronchoscopic images to assist transbronchial biopsy. *IEEE transactions on medical imaging*, 1998; 17(5): 703-714.
30. Ferretti G. R., Kocier M., Calaque O., Arbib F., Righini C., Coulomb M., Pison, C. Follow-up after stent insertion in the tracheobronchial tree: role of helical computed tomography in comparison with fiberoptic bronchoscopy. *European radiology*, 2003; 13(5): 1172-1178.
31. Bernhardt T., Schmid H., Philipp C., Allhoff E., Rapp-Bernhardt U. Diagnostic potential of virtual cystoscopy of the bladder: MRI vs CT. Preliminary report. *European radiology*, 2003; 13(2): 305-312.
32. Bakir B., Tüzün U., Terzibaşoğlu E., Dursun M., Güven K., Salmalıoğlu A., et al. The diagnostic efficiency of multislice CT virtual bronchoscopy in detecting endobronchial tumors. *Tuberkuloz ve toraks*, 2008; 56(1): 43-49.
33. Horton K. M., Horton M. R., Fishman, E. K. Advanced visualization of airways with 64-MDCT: 3D mapping and virtual bronchoscopy. *American Journal of Roentgenology*, 2007; 189(6): 1387-1396.
34. Van Der Drift M. A., Van Der Wilt, G. J., Thunnissen, F. B., Janssen J. P. A prospective study of the timing and cost-effectiveness of bronchial washing during bronchoscopy for pulmonary malignant tumors. *Chest*, 2005; 128(1): 394-400.
35. Lam W. K., So S. Y., Hsu C., Yu D. Y. Fiberoptic bronchoscopy in the diagnosis of bronchial cancer: comparison of washings, brushings and biopsies in central and peripheral tumours. *Clinical oncology*, 1983; 9(1): 35-42.
36. Hopper K. D., Lucas T. A., Gleeson K., Stauffer J. L., Bascom, R., Mauger, D. T., Mahraj, R. Transbronchial biopsy with virtual CT bronchoscopy and nodal highlighting. *Radiology*, 2001; 221(2): 531-536.
37. Shinagawa N., Yamazaki K., Onodera Y., Miyasaka K., Kikuchi E., Dosaka-Akita, H., Nishimura, M. CT-guided transbronchial biopsy using an ultrathin bronchoscope with virtual bronchoscopic navigation. *Chest*, 2004; 125(3):1138-1143.

## The effect of injury type and location on the prognosis of the patients with open globe injuries

Cezmi Dogan<sup>1\*</sup>, Burak Mergen<sup>1</sup>, Seda Sert<sup>1</sup>, Gulsah Tezcan<sup>1</sup>, Busenur Gonen<sup>1</sup>, Umit Yasar Guleser<sup>1</sup>, Osman Sevki Arslan<sup>1</sup>

### Abstract

**Objective:** Investigation of the effect of the globe injury site and the globe injury type on the postoperative results in the patients with a relatively softer open globe injury (OGI) was aimed.

**Methods:** Medical records of the patients with OGI due to blunt or penetrating trauma were analyzed retrospectively. The patient cohort was divided into laceration and rupture groups. The location of injury was evaluated in zones (I-II-III). Presence and type of the complication (cataract, retinal detachment, etc.) were evaluated. Final best corrected visual acuity (BCVA) was evaluated as the primary outcome measure.

**Results:** Seventy eyes of 70 patients with OGI were included in the study. While 58 eyes (82.9%) had lacerations, 12 eyes (17.1%) had ruptures. Among the 52 patients with lacerations for whom there was an available BCVA data, 13 (25%) patients showed no change, 32 (61.5%) showed an increase, and 7 (13.5%) showed a decrease in BCVA. Among the 11 patients with ruptures, 2 (18.2%) patients showed no change and 9 (81.8%) showed an increase in BCVA. A complication was observed in 23 (44.2%) patients with laceration and 4 (33.3%) patients with rupture (p: 0.474). No difference was detected in terms of the complication rate between the patients having a different zone of injury. However, final BCVA was lower in those with Zone III injury in comparison to those with Zone II injury (p: 0.028).

**Conclusion:** Although the injury type was thought to have an effect on the final BCVA of the patients with OGI, no difference was detected between the patients with laceration and rupture. Zone III injuries resulted in lower preoperative BCVA values. However, despite a significant difference between Zone II and III injuries, no significant difference was observed in terms of the final BCVA between the patients with Zone I and those with Zone III injuries.

**Keywords:** open globe injury; injury location; laceration; rupture; penetrating trauma

### Introduction

Ocular traumas are one of the most common ophthalmological emergencies and can cause globe injuries with varying severities. The type of trauma (mechanical, thermal, and chemical) is important in the prognosis of the globe injury. Mechanical traumas can cause lacerations (with a sharp object) or ruptures (caused by a blunt object) leading to open or closed globe injuries. In case of a full-thickness injury within the wall of the globe (cornea and sclera), it is called open globe injury, whereas partial-thickness injury is observed in case of a closed globe injury. In case of an open globe injury, the patient should be surgically managed urgently by primary closure of the wound. Because of a full-thickness injury, post-traumatic complication rates are higher in comparison to closed globe injuries (1,2).

Thus, open globe injuries possess a higher risk of blindness in comparison to closed globe injuries. Globe injuries are among the most common risk factors for unilateral blindness and most of them are preventable. According to the World Health Organization (WHO), approximately 1.6 million blind people, 2.3 million people with bilateral low vision, and almost 19 million people with unilateral blindness or low vision from injuries were observed (3).

Numerous studies have been conducted to predict the prognosis of patients with open globe injuries (4–6). Risk factors to show poor prognosis were reported including but not limited to age, preoperative visual acuity (VA), mechanism of injury, location and extent of damage (zone of injury), afferent pupillary defect, time lapse between the injury and surgery, presence of complications such as



traumatic cataract, severe intraocular hemorrhage, choroidal damage etc., presence of endophthalmitis (5,7–10). Although some studies linked the blunt trauma to a poor prognosis, Schmidt et al. showed that patients with penetrating trauma resulted in a worse final VA (11). To investigate this conflict, the effect of different injury mechanisms on the final VA should be studied.

In this study, investigation of the effect of the globe injury site and the globe injury type on the postoperative results in the patients with a relatively softer open globe injury was aimed.

## Methods

The patients who were referred to the Department of Ophthalmology in Cerrahpasa Medical Faculty with open globe injury due to blunt or penetrating trauma between 2010 - 2018 were analyzed retrospectively. Since it was a retrospective study, it was not necessary to obtain informed consent from the patients. The study has been carried out in accordance with the Declaration of Helsinki.

Only the patients with mechanical injuries were included in the study. The patients with caustic injuries or thermal injuries were excluded from the study. The patients with coexisting injuries other than globe injury such as the eyelid, orbital, and optic nerve injuries were also excluded from the study. Additionally, military or terror-related injuries were excluded from the study to create a group of patients with softer injuries. Then the patient cohort was divided into two groups; laceration (1) secondary to penetrating trauma and rupture (2) secondary to blunt trauma according to Birmingham Eye Trauma Terminology (12).

The age, gender, preoperative and final best corrected visual acuity (BCVA) testing with the logarithm of the minimum angle of resolution (logMAR) measurements, presence of complication and type of complication (formation of traumatic cataract, retinal detachment, vitreous hemorrhage, posterior synechia, peripheral anterior synechia) were recorded for all patients. The patients were categorized according to their best corrected visual acuity (BCVA) into three groups; (1) increased BCVA, (2) decreased BCVA, and (3) no change in BCVA. The patients with no light perception were excluded from the statistical analysis of logMAR equivalent of BCVA.

Repair of the perforated area with primary suturing was performed for seventy eyes of 70 patients included in the study. Detailed slit-lamp and fundusoscopic examination were done for all of the patients. B-scan ultrasonography was performed to reveal the posterior segment pathologies for the patients who had a pathology preventing the visualization of the posterior segment. Phacoemulsification and intraocular lens implantation were performed for patients with traumatic cataract who were thought to benefit from cataract surgery in terms of an increase in the BCVA.

Additionally, the location of injury was determined according to the Ocular Trauma Classification Group (2). Injuries located to the cornea and limbus were defined as Zone I injuries. Zone II injuries involved the anterior 5 mm

of the sclera (not extending into the retina). Zone III injuries involved full-thickness scleral defects more posterior than 5 mm from the limbus.

## Statistical analysis

A chi-square or Fisher test was utilized to compare the ratios. A Mann Whitney U test was used to compare the means of the independent groups. Kruskal Wallis test was used for the comparison of multiple independent groups and a Mann Whitney U test with Bonferroni correction was utilized for post hoc analysis. p value below 0.05 was considered statistically significant. SPSS (version 21.0) software was used in all statistical analyses.

## Results

Seventy eyes of 70 patients with open globe injury were included in the study. While 58 eyes (82.9%) had lacerations, 12 eyes (17.1%) had ruptures. The mean age of the patients with lacerations were  $28.7 \pm 20.7$  (3-82) years and it was  $37.2 \pm 20.3$  (2-74) years for the patients with ruptures. While 41 (70.7%) of 58 patients with lacerations were male and 17 (29.3%) were female, 9 (75%) of 12 patients with ruptures were male and 3 (25%) were female. The groups were homogenous in terms of age and gender (p: 0.17 and p: 0.534). The mean duration of follow up for the patients with laceration was  $29.3 \pm 10.6$  months (12-60 months) and it was  $29.8 \pm 7.4$  months (15-39 months) for the patients with rupture (p: 0.75). The most common complications observed in our patient cohort were traumatic cataract (21.5%), retinal detachment (10.0%), and vitreous hemorrhage (5.7%).

Among the 52 patients with lacerations for whom there was an available BCVA data, 13 (25%) patients showed no change in BCVA, 32 (61.5%) showed an increase in BCVA, and 7 (13.5%) showed a decrease in BCVA. Among the 11 patients with ruptures for whom there was an available BCVA data, 2 (18.2%) patients showed no change in BCVA and 9 (81.8%) showed an increase in BCVA. A total of 7 patients were children without verbal communication or patients with mental retardation whose BCVA data were not available. When both groups were compared, no significant difference was detected in terms of increase, decrease or no change in BCVA (p: 0.328). The mean BCVA of the patients with laceration was  $2.03 \pm 1.13$  before the operation and changed to  $1.33 \pm 1.3$  after the follow-up. The mean BCVA of the patients with rupture was  $2.17 \pm 1.06$  before the operation and changed to  $0.66 \pm 0.77$  after the follow-up. No significant difference was observed between the groups in terms of the BCVA before the operation and final BCVA (p: 0.67 and p: 0.38, respectively). When the patients were compared according to the injury type in terms of the frequency of complications secondary to the perforation (traumatic cataract, retinal detachment, vitreous hemorrhage, posterior synechia, peripheral anterior synechia), complication was observed in 23 (44.2%) patients with laceration and 4 (33.3%) patients with rupture (p: 0.474).

When the patients were evaluated in terms of the anatomical location of the perforation 29 patients (41.4%) had Zone I injury, 19 patients (27.1%) had Zone II injury,

and 22 patients (31.4%) had Zone III injury. Comparison of the patients according to the perforation location in terms of the change in BCVA is shown in Table 3. While the mean preoperative BCVA of the patients with Zone I injury was  $1.82\pm 0.97$ , it was  $1.64\pm 1.36$  for those with Zone II injury, and  $2.67\pm 0.81$  for those with Zone III injury ( $p: 0.01$ ). Comparison of the groups with post hoc Mann Whitney U test resulted in a significant difference between Zone I-III and Zone II-III ( $p: 0.025$  and  $p: 0.026$ , respectively).

While the mean final BCVA of the patients with Zone I injury was  $1.07\pm 1.13$ , it was  $0.81\pm 1.26$  for those with Zone II injury, and  $1.97\pm 1.24$  for those with Zone III injury ( $p: 0.021$ ). Comparison of the groups with post hoc Mann Whitney U test resulted in a significant difference between the patients with Zone II and Zone III injuries ( $p: 0.028$ ). However, when these groups were compared in terms of the complication rate, no significant difference was detected ( $p: 0.14$ ) (Table 4).

**Table 1.** The relationship between the injury type and the change in best corrected visual acuity

| Injury type  | Best Corrected Visual Acuity |           |           | Total     |
|--------------|------------------------------|-----------|-----------|-----------|
|              | No change                    | Increased | Decreased |           |
| Laceration   | 13                           | 32        | 7         | 52        |
| Rupture      | 2                            | 9         | 0         | 11        |
| <b>Total</b> | <b>15</b>                    | <b>41</b> | <b>7</b>  | <b>63</b> |

**Table 2.** Relationship between the injury type and the rate of complication

| Injury type  | Complication |           | Total     |
|--------------|--------------|-----------|-----------|
|              | Absent       | Present   |           |
| Laceration   | 35           | 23        | 58        |
| Rupture      | 8            | 4         | 12        |
| <b>Total</b> | <b>43</b>    | <b>27</b> | <b>70</b> |

**Table 3.** The relationship between the zone of injury and the change in best corrected visual acuity

| Zone of injury | Best Corrected Visual Acuity |           |           | Total     |
|----------------|------------------------------|-----------|-----------|-----------|
|                | No change                    | Increased | Decreased |           |
| Zone I         | 3                            | 19        | 4         | 26        |
| Zone II        | 7                            | 9         | 0         | 16        |
| Zone III       | 5                            | 13        | 3         | 21        |
| <b>Total</b>   | <b>15</b>                    | <b>41</b> | <b>7</b>  | <b>63</b> |

**Table 4.** Relationship between the zone of injury and the rate of complication

| Zone of injury | Complication |           | Total     |
|----------------|--------------|-----------|-----------|
|                | Absent       | Present   |           |
| Zone I         | 21           | 8         | 29        |
| Zone II        | 12           | 7         | 19        |
| Zone III       | 10           | 12        | 22        |
| <b>Total</b>   | <b>43</b>    | <b>27</b> | <b>70</b> |

## Discussion

In this retrospective study, the patients were divided into two groups as lacerations due to penetrating injuries and ruptures due to blunt injuries. When the patients were compared according to the injury type of the perforation, no significant difference was detected between the groups in terms of the frequency of post-traumatic complications and change in BCVA. However, when the patients were compared in terms of the location of the injury, the patients with Zone III injury had lower final BCVA values.

Several studies investigated the risk factors affecting the final VA and various risk factors were determined. Age, preoperative VA, mechanism of injury, location and extent of damage (zone of injury), afferent pupillary defect, the time lapse between the injury and surgery, presence of complications such as traumatic cataract, severe intraocular hemorrhage, choroidal damage, etc. were among the reported risk factors (5,7–10).

Some studies reported rupture secondary to blunt trauma as a risk factor for a poor prognosis as well (7,13) and in the study by Schmidt et al., the authors showed that postoperative change in visual acuity was better in the patients with ruptures (11). Thus, the effect of the mechanism of injury on the final VA was evaluated in this study. However, no significant difference was detected between the laceration and rupture groups in terms of the final BCVA. This might be related to the similar complication rates between the groups.

The open globe injuries (OGIs) are observed more frequently in male patients. In our study, consistent with the previous studies (14, 15), 70% of the patients with penetrating injury and 75% of the patients with blunt trauma were male. Although Guven et al. reported 24.3% of bilateral OGIs (14), since no patient was injured due to terror-related reasons, no patient showed bilateral injury in our study.

The frequency of penetrating trauma was found to be higher in the previous studies as in our study. Consistent with 82.9% of penetrating trauma in our study, Agrawal et al. reported 71.4% of penetrating trauma in their study (8). Although penetrating trauma was observed more frequently and no difference was detected between the laceration and rupture groups, we observed interestingly that bottle cap was the etiological factor causing injury in 2 patients and their final VA was no light perception. Then, we hypothesized that the pressure and the proximity of the etiological factor might be related to the severity of the injury. However, further studies investigating the impact of these parameters on the prognosis are necessary.

Ocular Trauma Classification Group proposed a system for locating the OGIs to predict the prognosis of the patients. According to this system, zone III injuries were found to be related to a poor prognosis in many studies (14, 16). Consistent with the previous literature, the patients with Zone III injury showed lower final BCVA values in comparison to those with Zone II injuries. However, no difference was detected between the patients with Zone I and III injuries.

This difference can be linked to the relatively low number of patients, absence of an intraocular foreign body in our patients, and non-military etiology. In our study, change in visual acuity was evaluated with logMAR equivalent of BCVA, while in the other studies varying range of VA were used for the categorization (14). Furthermore, since corneal perforation scars on the optical axis can dramatically decrease the visual acuity in cases with Zone I injury, the classification of the location according to the zones can be an insufficient approach. Thus, a newer classification system with a special emphasis on the central or paracentral corneal location of the wound might be proposed.

After the open globe injury, the most commonly affected locations are the most vulnerable parts of the globe. For example, blunt trauma affects more commonly the sclera rather than cornea. Additionally, surgical wounds are another example of the vulnerable site of the globe during the injury. For example, in patients with a keratoplasty

history, the most vulnerable site is expected to be the donor graft interface. However, in one of our patients with a history of keratoplasty, a blunt trauma interestingly caused scleral rupture. The presence of blue sclera or etiological factors such as connective tissue disorders that might cause a decreased scleral rigidity was investigated and no pathology was discovered (17). Thus, perforation through the surgical wound might not be a certain rule.

The most commonly observed complications after the open globe injury was traumatic cataract and retinal detachment in our study. Traumatic cataract was reported as the most common post-traumatic complication in most of the previous studies (18). However, contrary to the other studies (1, 18, 19), intraocular foreign body, and aphakia after initial trauma were not observed in our patients. Absence of these post-traumatic complications might also be linked to the indifference observed in our study between the patients with Zone I and Zone III injury in terms of the final BCVA.

The rate of endophthalmitis after open globe injuries has been reported between 0.9-6.7% (20-23). In our study, endophthalmitis was not observed in any of the patients. Risk factors related to an increased frequency of post-traumatic endophthalmitis have been reported as a delayed presentation (>24 hours), microbial keratitis, and lens capsule breach (21). In our study, all of the patients were operated earlier than 24 hours after the trauma and intraocular foreign body was not observed in any of the patients. Additionally, intracameral moxifloxacin was applied to all of the patients at the end of the surgery contrary to the study by Essex et al. where the authors did not apply any intracameral antibiotic to any of their patients (22). Absence of endophthalmitis in our patient cohort might be related to these differences.

## Conclusion

In conclusion, our series of patients with relatively softer OGIs presenting to a tertiary referral center has shown no difference in terms of final BCVA and complication rate according to the injury type (laceration or rupture). Although the preoperative mean BCVA was lower in the patients with Zone III injury, final mean BCVA values showed no significant difference between patients with Zone I and III injuries.

No significant difference was observed in terms of the complication rates between the patients with different zone injuries. These differences might be attributed to the selection of a group of patients with relatively softer injuries. Limitations of the study were its retrospective design and the absence of the pupillary afferent defect data. Further studies are necessary to investigate more precise risk factors (especially central corneal location) for the prediction of the prognosis after open globe injuries.

**Acknowledgements:** None

**Conflict of Interest:** The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Author's Contributions: CD, BM, SS, GT, BG, UYG, OSA;** Research concept and design, Patient examinations, Research the literature, preparation of the article. Chemical Analysis. **CD;** Revision of the article.

## References

- Al-Mezaine HS, Osman EA, Kangave D, Abu El-Asrar AM. Prognostic factors after repair of open globe injuries. *J Trauma*. 2010;69(4):943–7.
- Pieramici DJ, Sternberg P, Aaberg TM, Bridges WZ, Capone A, Cardillo JA, et al. A system for classifying mechanical injuries of the eye (globe). The Ocular Trauma Classification Group. *Am J Ophthalmol*. 1997 Jun;123(6):820–31.
- Négrel AD, Thylefors B. The global impact of eye injuries. *Ophthalmic Epidemiol*. 1998;5(3):143–69.
- Pimolrat W, Choovuthayakorn J, Watanachai N, Patikulsilta D, Kunavisarut P, Chaikitmongkol V, et al. Predictive factors of open globe injury in patients requiring vitrectomy. *Injury*. 2014;
- Feng K, Hu YT, Ma Z. Prognostic Indicators for No Light Perception After Open-Globe Injury: Eye Injury Vitrectomy Study. *Am J Ophthalmol*. 2011 Oct;152(4):654–662.e2.
- Page RD, Gupta SK, Jenkins TL, Karcioğlu ZA. Risk factors for poor outcomes in patients with open-globe injuries. *Clin Ophthalmol*. 2016;10:1461–6.
- Agrawal R, Ho SW, Teoh S. Pre-operative variables affecting final vision outcome with a critical review of ocular trauma classification for posterior open globe (zone III) injury. *Indian J Ophthalmol*. 2013;61(10):541–5.
- Agrawal R, Naigaonkar R, Desai S, Rao G, Ou X. Prognostic factors for vision outcome after surgical repair of open globe injuries. *Indian J Ophthalmol*. 2011;59(6):465.
- Feng K, Shen L, Pang X, Jiang Y, Nie H, Wang Z, et al. Case-control study of risk factors for no light perception after open-globe injury: Eye injury vitrectomy study. *Retina*. 2011 Nov;31(10):1988–96.
- Kuhn F, Mester V, Berta A, Morris R. [Epidemiology of severe eye injuries. United States Eye Injury Registry (USEIR) and Hungarian Eye Injury Registry (HEIR)]. *Ophthalmologie*. 1998 May;95(5):332–43.
- Schmidt GW, Broman AT, Hindman HB, Grant MP. Vision Survival after Open Globe Injury Predicted by Classification and Regression Tree Analysis. *Ophthalmology*. 2008;
- Kuhn F, Morris R, Witherspoon CD, Mester V. The Birmingham Eye Trauma Terminology system (BETT). *J Fr Ophthalmol*. 2004 Feb;27(2):206–10.
- Savar A, Andreoli MT, Kloek CE, Andreoli CM. Enucleation for Open Globe Injury. *Am J Ophthalmol*. 2009 Apr;147(4):595–600.e1.
- Güven S, Durukan AH, Erdurman C, Kucukcilioglu M. Prognostic factors for open-globe injuries: variables for poor visual outcome. *Eye*. 2019 Mar;33(3):392–7.
- Oner A, Kekec Z, Karakucuk S, Krakucuk S, İkizceli I, Sözüer EM. Ocular trauma in Turkey: a 2-year prospective study. *Adv Ther*. 23(2):274–83.
- Qi Y, Zhang F-Y, Peng G-H, Zhu Y, Wan G-M, Wang W-Z, et al. Characteristics and visual outcomes of patients hospitalized for ocular trauma in central China: 2006-2011. *Int J Ophthalmol* [Internet]. 2015 [cited 2019 Jul 12];8(1):162–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25709927>
- Arici C, Hagverdiyeva S, Mergen B, Mangan MS, Arslan OS. First report of traumatic scleral rupture after penetrating keratoplasty. *Turkish J Trauma Emerg Surg* [Internet]. 2019;25(5):0. Available from: <https://dx.doi.org/10.5505/tjtes.2018.55014>
- Gursoy H, Bilgec MD, Sahin A, Colak E. A Possible Regression Equation for Predicting Visual Outcomes after Surgical Repair of Open Globe Injuries. *J Ophthalmol*. 2017;2017:1320457.
- Sahin Atik S, Ugurlu S, Egrilmez ED. Open Globe Injury: Demographic and Clinical Features. *J Craniofac Surg*. 2018 May;29(3):628–31.
- Andreoli CM, Andreoli MT, Kloek CE, Ahuero AE, Vavvas D, Durand ML. Low Rate of Endophthalmitis in a Large Series of Open Globe Injuries. *Am J Ophthalmol*. 2009 Apr;147(4):601–608.e2.
- Kong GYX, Henderson RH, Sandhu SS, Essex RW, Allen PJ, Campbell WG. Wound-related complications and clinical outcomes following open globe injury repair. *Clin Experiment Ophthalmol*. 2015;43(6):508–13.
- Essex RW, Yi Q, Charles PGP, Allen PJ. Post-traumatic endophthalmitis. *Ophthalmology*. 2004 Nov;111(11):2015–22.
- Duch-Samper AM, Menezes JL, Hurtado-Sarrió M. Endophthalmitis following penetrating eye injuries. *Acta Ophthalmol Scand*. 1997 Feb;75(1):104–6.

Copyright © 2019 The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), (CC BY NC) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. *International journal of Medical Science and Discovery*.



## Evaluation and treatment of the eosinophilic lung diseases in 7 patients

Tugce Uzar<sup>1</sup>, Gozde Duyu<sup>1</sup>, Adem Dirican<sup>2</sup>, Selda Gunaydin<sup>3</sup>, Hayriye Bektas Aksoy<sup>3</sup>, Nazlı Topbası<sup>4</sup>,  
Hulya Bayiz<sup>4</sup>, Sevket Ozkaya<sup>4\*</sup>

### Abstract

**Objective:** Eosinophilic lung diseases (ELD) are a rare group of heterogeneous diseases characterized by increase of the eosinophilic ratio in the airways and lung parenchyma. We aimed to present and discuss the clinical, radiologic and pathologic features of six patients with eosinophilic lung diseases.

**Conclusion:** Peripheral eosinophilia with pulmonary infiltrates is diagnostic clues of eosinophilic lung diseases. Systemic corticosteroids are provided rapid control not only in symptoms but also radiological and clinical improvement of ELD.

**Keywords:** eosinophilic lung diseases, acute eosinophilic pneumonia, chronic eosinophilic pneumonia

### Introduction

Eosinophilic lung diseases are a rare group of heterogeneous diseases characterized by increase of the eosinophilic ratio in the airways and lung parenchyma.(1) They are classified as eosinophilic lung diseases of unknown cause including simple pulmonary eosinophilia, acute eosinophilic pneumonia, chronic eosinophilic pneumonia, idiopathic hypereosinophilic syndrome and eosinophilic lung diseases of known cause; including allergic bronchopulmonary aspergillosis, bronchocentric granulomatosis, parasitic infections, drug reactions, eosinophilic vasculitis (allergic angiitis, granulomatosis (Churg-Strauss syndrome) (2). We aimed to present and discuss the clinical, radiologic and pathologic features of patients with eosinophilic lung diseases.

### Material and Methods

We retrospectively evaluated the patients whom diagnosed with eosinophilic lung diseases between January 2013 and January 2018 in the Department of Pulmonary Medicine, VM Medicalpark Samsun Hospital, Samsun, Turkey. The clinical-radiological findings, performed treatments, responses to treatment, and prognoses of patients who diagnosed with eosinophilic lung diseases were retrospectively evaluated. The study was performed in accordance with the ethical principles in the Good Clinical Practice (GCP) guidelines, applicable local regulatory requirements, and the protocol was approved by local ethics review boards. All the patients read the patient information form about the study procedure and written informed consent forms were obtained.

Received 13-05-2019 Accepted 09-07-2019 Available Online 24-07-2019 Published 30-07-2019

1 Bahcesehir University, Faculty of Medicine, Medical Student/Intern, Istanbul, TR.

2 Samsun Medicalpark Hospital, Dept of Pulmonary Medicine, Samsun, TR.

3 Giresun University, Faculty of Medicine, Dept of PulmonaryMedicine, Giresun, TR.

4 Bahcesehir University, Faculty of Medicine, Dept of PulmonaryMedicine, Istanbul, TR.

\* Corresponding Author: Şevkey Özkaya E-mail: [ozkayasevket@yahoo.com](mailto:ozkayasevket@yahoo.com) Phone: +90 532 474 13 09




**Case 1: Atelectasis and respiratory failure due to allergic bronchopulmonary aspergillosis (ABPA) in a patients with severe asthma**


A 52-year-old non-smoker female patient was referred to our Intensive Care Unit due to respiratory failure with pulmonary atelectasis, pulmonary mass and consolidations. She was suffering from severe dyspnea due to severe asthma and her asthma had not been controlled with optimal asthma treatment. Chest radiograph showed volume loss with opacity on left hemithorax and consolidations on right hemithorax (Figure 1A). Thoracic CT has indicated to left upper lobe atelectasis, interlobular septal thickening with pulmonary mass and dense consolidations on right lung (Arrow in Figure 1B). Despite suspicion of malignancy, her 3 months prior Thorax CT was better than now (Figure 1C).

We thought that severe asthma, atelectasis and respiratory failure may be caused from Allergic Bronchopulmonary Aspergillosis (ABPA). Laboratory findings revealed that the total IgE level was 2430IU/ml. Aspergillus skin test and sputum culture for Aspergillus species were positive. The systemic corticosteroid treatment was started for diagnosis of “Severe asthma, Atelectasis and Respiratory Failure Due To Allergic Bronchopulmonary Aspergillosis (ABPA)”.


At the 2nd day of treatment atelectasis and pulmonary consolidations were rapidly improved (Figure 1B ). Four weeks after the treatment, atelectasis and pulmonary consolidations were recovered and fungal cavitory lesion due to aspergillus was noted on right lung (Arrow in Figure 1D).




**Figure 1A.** Chest radiograph showed the volume loss with opacity on left hemithorax and consolidations on right hemithorax (Figure 1AA). The systemic corticosteroid treatment was started and at the 2nd day of treatment atelectasis and pulmonary consolidations were rapidly improved (Figure 1BB).



**Figure 1B.** Thorax CT showed the left upper lobe atelectasis, interlobular septal thickening with pulmonary mass and dense consolidations on right lung.



**Figure 1C.** Three months prior Thoracic CT findings of patient was were better than now. Due to this data, the malignancy probability removed from possibilities.




**Figure 1D.** Atelectasis and pulmonary consolidations were recovered and fungal cavitory lesion due to aspergillus was noted on right lung after 4 weeks of treatment.

**Case 2: Allergic aspergillosis in an uncontrolled asthmatic patient**

A 42-year-old non-smoker man with uncontrolled severe asthma was referred to our hospital. He was suffering from persistent wheezing, cough and dyspnea and his asthma had not been controlled with optimal asthma treatment. Thoracic CT performed for to definite diagnosis of “Uncontrolled Asthma” and it revealed the infiltrates on right middle lobe and peripheral cavitary lesion which includes an opacity (Figure 2A).

Laboratuary findings; Total IgE level was 6000 IU/ml and white blood cell count was 6410/uL with eosinophils of 1090/ uL (17%). Aspergillus skin test performed and it was positive. The systemic corticosteroid and itrakonazol treatments were started for the diagnosis of “Allergic Aspergillosis with Uncontrolled Asthma”. After the treatment, symptoms and pulmonary lesions were improved (Figure 2B).




**Figure 2A.** Thoracic CT performed for to definite diagnosis of “*Uncontrolled Asthma*” and it revealed the infiltrates on right middle lobe and peripheral cavitary lesion which include a opacity(Figure 2AA). After the treatment, the symptoms and pulmonary lesions were improved (Figure 2BB).

**Figure 2B.** Thorax CT showed the left upper lobe atelectasis, ininterlobular septal thickening with pulmonary mass and dense consolidations on right lung.


**Case 3: Chronic Eosinophilic Pneumonia with Respiratory Failure**

A 65-year-old man, referred to our Intensive Care Unit for complaints of cough, dyspnea and hypoxemic respiratory failure. Chest radiograph showed bilateral reticular infiltrates on upper fields of lung.(Figure 3A). Despite the treatment for pneumonia with levofloxacin and piperasilin/tazobactam, his radiologic features and symptoms were worsening. Thoracic CT was performed for the definitive diagnosis of “non-responding pneumonia“. Thoracic CT scans demonstrated the bilateral non-segmental airspace consolidations with peripheral predominance on upper lobes of lungs which were consistent with “ photographic negative shadow of pulmonary edema” (Figure 3B).

Finding of photographic negative shadow of pulmonary edema was consistent with Chronic Eosinophilic Pneumonia. His white blood cell count was 24110/uL with eosinophils of 16730/ uL (69.4%). The systemic corticosteroid treatment was started for diagnosis of Chronic Eosinophilic Pneumonia with respiratory failure. After the 3 days of corticosteroid treatment, the respiratory failure and alveolar consolidations were rapidly recovered (Figure 3C).




**Figure 3A.** Chest radiograph showed bilateral reticular infiltrates on upper fields of lung.



**Figure 3B.** Thoracic CT scans demonstrated the bilateral non-segmental airspace consolidations with peripheral predominance on upper lobes of lungs which it was consistent with “ photographic negative shadow of pulmonary edema”.




**Figure 3C:** After the 3 days of corticosteroid treatment, respiratory failure and alveolar consolidations were rapidly recovered




**Case 4: Löffler Pneumonia**

A 50-year-old non-smoker male admitted to our clinic with dry cough and dyspnea. Thorax CT revealed bilateral fleeting migratory pulmonary nodular opacities (Figure 4A). Lesions did not respond to the antibiotic treatment and malignancy was ruled out with 18 FDG PET/CT scan.

His white blood cell count was 13260 K/uL with eosinophils of 4950 K/ uL(37.3%). The systemic corticosteroid treatment was started for the diagnosis of Löffler Pneumonia and alveolar consolidations were rapidly recovered within 10 days after the corticosteroid treatment (Figure 4B).



**Figure 4A.** Thorax CT revealed the bilateral fleeting migratory pulmonary nodular opacities.



**Figure 4B.** The systemic corticosteroid treatment was started for diagnosis of Löffler Pneumonia and alveolar consolidations were rapidly recovered within 10 days after the treatment.


### Case 5: Eosinophilic mass in a asthmatic patient

A 38 years old male admitted to the hospital with complaints of dyspnea and cough. He had diagnosis of asthma and rhoncus were noted on chest auscultation. Chest radiography showed the plate-like atelectasis on left hemithorax. Thoracic CT scan images revealed the peribronchial mass like pulmonary lesion with atelectasis (Figure 5A).


Fiberoptic bronchoscopy was performed and there was a white colour endobronchial mass in left lower lobe bronchus. Biopsies were taken from endobronchial mass and histopathologic examination showed the eosinophilic inflammatory infiltration (Figure 5B). After the corticosteroid treatment, pulmonary mass was fully recovered (Figure 5C).



**Figure 5A.** Thoracic CT scan images revealed the peribronchial mass like pulmonary lesion with atelectasis



**Figure 5B.** The histopathologic image showing the eosinophilic infiltration.



**Figure 5C.** After the corticosteroid treatment, pulmonary mass was fully recovered.


### Case 6: Chronic Eosinophilic Pneumonia

A 54 year-old female referred to our clinic with complaints of cough, dyspnea and unresolved pneumonic infiltrations. Chest radiograph showed bilateral reticular infiltrates (Figure 6A). Thoracic CT scans demonstrated the bilateral non-segmental airspace consolidations with peripheral predominance on upper lobes of lungs which were consistent with “photographic negative shadow of pulmonary edema” (Figure 6B).

The finding of photographic negative shadow of pulmonary edema was consistent with Chronic Eosinophilic Pneumonia. His white blood cell count was 13790 K/uL with eosinophils of 5710 K/uL (41.4%) . Systemic corticosteroid treatment was started for the diagnosis of Chronic Eosinophilic Pneumonia with respiratory failure. After the corticosteroid treatment, the alveolar infiltrates were resolved (Figure 6C and 6D).




**Figure 6A.** Chest radiograph showed bilateral reticular infiltrates.



**Figure 6B.** Thoracic CT scans demonstrated the bilateral non-segmental airspace consolidations with peripheral predominance which it was consistent with “*photographic negative shadow of pulmonary edema*”.



**Figure 6C.** Chest radiography showed that after the corticosteroid treatment, the alveolar infiltrates were completely resolved.




**Figure 6D.** Thorax CT images showed that after the corticosteroid treatment, the alveolar infiltrates were completely resolved.


**Case 7: Acute Eosinophilic Pneumonia**

A 32 years old male referred to ICU for ARDS. His chest radiography showed the bilateral diffuse infiltrates (Figure 7A). Thoracic CT images revealed the bilateral diffuse alveolar-interstitial infiltrates with air bronchograms (Figure 7B). He was received antipsychotic, antidepressant and antiepileptic drugs including risperidone, quetiapine, carbamazepine, valproic acid (sodium valproate) due to schizophrenia and epilepsy.


His white blood cell count was 4860 K/uL with eosinophils of 0 K/uL (0%). We suspected from Acute Eosinophilic Pneumonia caused from risperidone and it was stopped. Systemic corticosteroid treatment was started for the diagnosis of Acute Eosinophilic Pneumonia with respiratory failure. After the corticosteroid treatment, the alveolar infiltrates and respiratory were rapidly resolved (Figure 7C).



**Figure 7A.** Chest radiography showing the bilateral diffuse infiltrates.



**Figure 7B.** Thoracic CT images showing the bilateral diffuse alveolar-interstitial infiltrates with air bronchograms.



**Figure 7C.** After the corticosteroid treatment, alveolar infiltrates and respiratory were rapidly resolved.



## Discussion

The eosinophil is a multifunctional leukocyte implicated in the pathogenesis of a wide range of inflammatory reactions. It modulates immune responses at the sites of inflammatory foci within several organ systems. Although several different normal values have been reported, normal blood generally contains 50–250 eosinophils per microliter (3,4).

Most eosinophilic lung diseases manifest with peripheral eosinophilia, although acute eosinophilic pneumonia (AEP) may not. Diagnosis is based on demonstration of opacities on chest x-ray and identification of eosinophilia (>450/ $\mu$ L) in peripheral blood, bronchoalveolar lavage fluid, or lung biopsy tissue.

The most valuable clinical information is derived from the patient's history and from physical examination. The duration and severity of symptoms are also of critical importance. CEP typically affects patients in their 30s or 40s, although onset in childhood has been reported. The disease has a gradual onset, with an interval of approximately four to five months between the appearance of initial symptoms and diagnosis.

Typical symptoms include a cough, fever, breathlessness, weight loss, and night sweats, as seen in our cases. Löffler syndrome, a form of eosinophilic pulmonary disease, is characterized by absent or mild respiratory symptoms (most often dry cough), fleeting migratory pulmonary opacities, and peripheral blood eosinophilia. Parasitic infections, especially *Ascaris lumbricoides*, may be the cause, but an identifiable etiologic agent is not found in up to one third of patients.

Treatment of Löffler syndrome may consist of corticosteroids. Pulmonary function tests can occasionally be useful in the evaluation of patients with unexplained pulmonary eosinophilia. Some eosinophilic lung diseases (Acute Eosinophilic Pneumonia (AEP), Chronic Eosinophilic Pneumonia (CEP), tropical pulmonary eosinophilia) are typically accompanied by mainly restrictive ventilatory defects, whereas others (ABPA, Churg-Strauss syndrome) typically cause mainly obstructive ventilatory defects. Bronchoalveolar Lavage (BAL) can also be very useful in the evaluation of patients with eosinophilic lung disease (10).

Normal BAL fluid consists of less than 1% eosinophils. Because some disorders are not accompanied by peripheral eosinophilia, BAL may provide the first (and, perhaps, the only) indication of an eosinophilic lung disease. Patients with eosinophilic lung disease may be identified initially on the basis of pulmonary symptoms or chest radiographic abnormalities accompanied by blood or tissue eosinophilia. Diverse and nonspecific findings may also be seen at conventional chest radiography.

Chest computed tomography (CT) demonstrates a more characteristic pattern and distribution of parenchymal opacities than chest direct radiography. Although the characteristic CT findings are often helpful, there is still a considerable overlap of CT findings among the various eosinophilic lung diseases (5,6).

Acute eosinophilic pneumonia (AEP) is a rare and life-threatening clinic condition, as seen in our 6th case. Many causes such as collagen diseases, infections, irradiation, toxins, neoplasia and a long list of drugs can be implicated in the development of AEP (7).

Antibiotics and non-steroid anti-inflammatory drugs (NSAIDs) are the most commonly reported drugs associated with AEP.

Toxins suspected of causing eosinophilic pneumonia include cigarette smoke and illicit drugs (cocaine, heroine). Drug- or toxin-induced eosinophilic pneumonia is indistinguishable from idiopathic acute or chronic eosinophilic pneumonia by clinical, radiographic, and histopathologic criteria. Diagnosis is supported by a temporal relationship to a drug or toxin. The condition usually resolves with removal of the agent and recurs with rechallenge (8).

Rizos et. al, reported the first case with risperidone-induced AEP (9). Eosinophils are exquisitely sensitive to corticosteroids and completely disappear from the bloodstream within a few hours after administration of corticosteroids. This rapid disappearance from the blood may obscure the diagnosis in patients who receive corticosteroids before the diagnostic assessment is instituted.

## Conclusion

Peripheral eosinophilia with pulmonary infiltrates are diagnostic clues of eosinophilic lung diseases. Systemic corticosteroids are provides rapid control not only in symptoms but also radiological and clinical improvement.

**Acknowledgements:** None

**Conflict of Interest:** The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Author's Contributions:** ÖOK, ÖMT, BÇ, İGÖ, BÇ; Research concept and design, Patient examinations, Research the literature, preparation of the article. Chemical Analysis. BÇ; Revision of the article.

## References

1. Aouadi S, Melki B, Braham E, et al. Eosinophilic lung disease. *Eur Respir J* 2016; 48.
2. Jeong YJ, Kim K, Seo JJ, et al. Eosinophilic Lung Diseases: A Clinical, Radiologic, and Pathologic Overview. *RadioGraphics* 2007; 27:617–639.
3. Bernheim A, McLoud T. A Review of Clinical and Imaging Findings in Eosinophilic Lung Diseases. *Am J of Roentgen*. 2017;208: 1002-1010.
4. Marchand E, Etienne-Mastroianni B, Chanez P, et al. Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other? *Eur Respir J* 2003; 22:8.
5. Allen JN, Davis WB. Eosinophilic lung diseases. *Am J Respir Crit Care Med* 1994;150:1423–1438.
6. Johkoh T, Muller NL, Akira M, et al. Eosinophilic lung diseases: diagnostic accuracy of thin-section CT in 111 patients. *Radiology* 2000;216:773–780.

7. Campos LE, Pereira LF. Pulmonary eosinophilia. *J Bras Pneumol* 35: 561-573, 2009.
8. Solomon J, Schwarz M. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. *Semin Respir Crit Care Med* 27(2): 192-197, 2006.
9. Rizos E, Tsigkaropoulou E, Lambrou P. Risperidone-induced Acute Eosinophilic Pneumonia. *In Vivo* 2013;27 (5): 651-653.
10. Mann B. Eosinophilic lung disease. *Clinical medicine. Circulatory, respiratory and pulmonary medicine*. 2008 Jan;2:CCRPM-S575.

Copyright © 2019 The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), (CC BY NC) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. *International journal of Medical Science and Discovery*.

# MSD

Medical Science & Discovery



International Journal of  
Medical Science and Discovery  
Open Access Scientific Journal  
ISSN: 2148-6832  
Lycia Press LONDON U.K.  
[www.medscidiscovery.com](http://www.medscidiscovery.com)



[www.lycians.com](http://www.lycians.com)